This piece teaches you to use the right part of the label, recognize the ingredients that disqualify a product immediately, understand what each one does to your metabolism in plain language, and apply a simple three-question framework before anything goes in your cart. It also covers artificial sweeteners: what the current evidence shows about their metabolic consequences so you can make informed choices.

The Right Part of the Label

Ingredients are listed by weight in descending order, that is the information you need. The nutrition facts panel still has four numbers worth checking, but the ingredient list is the primary tool.

A large prospective cohort study of 108,643 adults linked specific additive combinations to significantly higher incidence of type 2 diabetes (Lancet Series on Ultra-Processed Foods, Touvier M et al., November 2025). A separate 2025 laboratory study found that mixtures of additives caused toxic effects in human colon, liver, kidney, and neuron cell models that were not observed when the same substances were tested individually.

The Worst Offenders: What to Look for and Why It Matters

Industrial Sweeteners

High fructose corn syrup and its aliases: high fructose corn syrup (HFCS) bypasses the regulatory steps that normally govern glucose metabolism and is processed almost entirely in the liver, where it drives de novo lipogenesis, elevates triglycerides, and contributes to insulin resistance through a pathway that glucose does not share.

On ingredient lists, HFCS may appear as: corn syrup, corn syrup solids, glucose-fructose syrup, isoglucose, or high fructose maize syrup. If any of these aliases appears in the first five ingredients, the product is built on cheap industrial sweetener.

The sugar fragmentation problem: sugar has more than sixty names on ingredient lists. Manufacturers distribute it across multiple entries to prevent any single form from appearing prominently enough to alarm a scanning reader. Dextrose, maltose, maltodextrin, fruit juice concentrate, cane sugar, brown rice syrup, and agave nectar are all sugar by other names.

The one place the nutrition facts panel is genuinely useful is the added sugars line, which aggregates every form of added caloric sweetener into a single gram count, regardless of how many names they appear under. The World Health Organization (WHO) recommends staying below 50 grams of added sugar per day on a 2,000-calorie diet. A single serving of many breakfast cereals, flavored yogurts, or condiments can consume a substantial fraction of that budget.

Industrial Fats

Partially hydrogenated oils: partially hydrogenated oils are the source of artificial trans fats, and they are a disqualifying finding regardless of what the nutrition facts panel claims. Under current US labeling rules, a product with less than 0.5 grams of trans fat per serving can legally declare zero grams on the panel. A product consumed in two or three servings, as many packaged snacks are, can deliver meaningful trans fat exposure under a zero trans fat claim.

Fully hydrogenated oils and interesterified fats: these are the industrial replacements developed after the 2015 FDA determination that partially hydrogenated oils were no longer generally recognized as safe. They are not technically trans fats by regulatory definition, but they are present for the same industrial purpose: extending shelf life and modifying texture in ways that real food fats cannot match as cheaply. The long-term human metabolic evidence on these substitutes is limited.

Seed oils in the first five ingredients: soybean oil, corn oil, cottonseed oil, and sunflower oil appearing in the first five ingredients is a clear marker of industrial manufacturing independent of the omega-6 to omega-3 ratios.

Emulsifiers: The Most Important New Evidence

Carboxymethylcellulose (CMC) and polysorbate 80 (P80) have the strongest documented harm evidence. They thin the intestinal mucus layer that protects epithelial cells, increase gut permeability, elevate lipopolysaccharide (LPS) translocation into the bloodstream, and activate NF-kB inflammatory pathways with upregulation of TNF-alpha and interleukin-6 (IL-6). These are the mechanisms that drive chronic low-grade inflammation and propagate insulin resistance.

Chassaing B et al. demonstrated direct impact of CMC and P80 on human gut microbiota (Microbiome, 2021). A 2024 Communications Biology study confirmed that CMC and P80 induce intestinal inflammation and metabolic syndrome markers through gut permeability elevation and LPS translocation. The most recent and highest-quality human data comes from a 2025 placebo-controlled randomized controlled trial (RCT) of 60 healthy participants published in Clinical Gastroenterology and Hepatology: CMC consumption produced reduced short-chain fatty acid (SCFA) concentrations, and carrageenan produced significantly increased transcellular intestinal permeability compared to placebo.

On ingredient lists, emulsifiers appear as: carboxymethylcellulose, cellulose gum, polysorbate 80, carrageenan, mono and diglycerides, soy lecithin, xanthan gum, and guar gum.

Artificial Colors and Preservatives

Artificial colors: Red 40, Yellow 5, Yellow 6, Blue 1, and Blue 2 are petroleum-derived dyes added to make industrially manufactured products visually appealing. Their presence on an ingredient list is an unambiguous marker of industrial manufacturing. The regulatory landscape is shifting: in 2025, the FDA announced plans to phase out some petroleum-derived dyes from the US food supply, and California signed a law in 2025 legally defining UPF and phasing out the most harmful additives from public school meals.

Sodium benzoate and potassium benzoate: when combined with ascorbic acid in the same product, they can form benzene under certain conditions. Ascorbic acid used alone as a preservative is safe: it is vitamin C. The issue is specific to its combination with benzoate preservatives.

Butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT): are petroleum-derived antioxidant preservatives added to extend shelf life. They provide no nutritional benefit to the consumer. Their safety profiles remain contested in the scientific literature. Their presence on a label tells you the product required industrial chemistry to remain stable on a shelf.

Flavor Manipulation Ingredients

Natural flavors: covers a wide range of industrial flavor extracts derived from natural sources and processed through methods that bear little resemblance to home cooking. When natural flavors appear in the first five ingredients, the product’s flavor character is being engineered rather than delivered by the actual food ingredients.

Monosodium glutamate (MSG): the sodium salt of glutamic acid, an amino acid naturally abundant in fermented foods, aged cheeses, and many vegetables. In UPF, it functions as a palatability amplifier designed to make a product taste better.

The First Five Rule

Ingredients are listed by weight in descending order, the first five ingredients are the main ones. If any of the worst offenders described above appear in the first five positions, look for an alternate product.

Real food does not need a paragraph to explain itself. A product with twenty-two ingredients, half of them unpronounceable, is very likely not good for your metabolic health.

What to Actually Use on the Nutrition Facts Panel

Added sugars: aggregates every form of added caloric sweetener, including HFCS, corn syrup, dextrose, maltose, fruit juice concentrates, and all other forms, into a single gram count. The WHO recommendation is below 50 grams per day on a 2,000-calorie diet. Check this number against the serving size actually consumed, not the labeled serving.

Dietary fiber: a grain-based product delivering less than 1 gram of fiber per serving has been heavily refined. More than 3 grams represents a meaningful contribution.

Sodium: check against the potassium amount further down on the label. Ideally potassium should be higher or at least roughly equal to the sodium amount.

Serving size: manufacturers define serving sizes to produce numbers that look favorable. Every number on the nutrition facts panel multiplies by actual consumption. The calorie count that looked reasonable was calculated for a portion nobody eats.

If you enjoy evidence-based medical information, subscribe to receive these articles delivered to your mailbox every week.

Subscribe now

Artificial Sweeteners: What They Are, Where They Hide, and What the Evidence Shows

Sucralose (Splenda)

Sucralose is the most widely used sweetener in commercially available diet products and carries the most concerning evidence profile of the sweeteners covered here.

A 2025 triple-blind RCT by Romo-Romo A et al., published in Clinical Nutrition ESPEN, found that 30 days of sucralose consumption at just 30% of the acceptable daily intake (ADI) produced a 20.3% reduction in insulin sensitivity in healthy lean adults, accompanied by reduced microbial diversity, shifts in bacterial populations, and decreased butyrate. A separate 10-week open-label RCT found altered gut bacterial abundance and associated changes in glucose and insulin levels on tolerance testing at 48mg daily sucralose (Mendez-Garcia LA et al., Microorganisms, 2022). The landmark Suez J et al. 2022 RCT of 120 healthy adults published in Cell found that sucralose significantly impaired glycemic responses through microbiome-mediated mechanisms confirmed in mouse transfer experiments (Cell, 2022;185(18):3307-3328).

A 2025 brain imaging RCT from the University of Southern California found that sucralose increased hunger sensation by approximately 17% and increased connectivity in brain regions controlling motivation, leading the researchers to conclude that sucralose interferes with normal appetite regulation in ways that could adversely affect weight control (Page KA et al., Nature Metabolism, 2025).

The appetite disruption evidence across all non-caloric sweeteners remains heterogeneous in the broader human literature. For sucralose specifically, multiple independent RCTs are consistent in direction across microbiome disruption, insulin sensitivity reduction, and appetite dysregulation.

Saccharin (Sweet’N Low)

A large case-control study of 3,010 bladder cancer patients and 5,783 controls found no association with saccharin use. Saccharin was removed from the US National Toxicology Program’s (NTP) list of potential carcinogens in 2001. A 2024 meta-analysis in Minerva Surgery concluded the carcinogenic risk of saccharin is not proven in humans (Balint IB et al., Minerva Surg, 2024;79(1):92-99). The European Food Safety Authority’s (EFSA) 2024 reassessment raised the ADI and concluded the cancer risk in humans is low.

Saccharin’s legitimate metabolic concern in this series is gut microbiome disruption. The Suez et al. 2022 Cell RCT found saccharin significantly impaired glycemic responses through microbiome-mediated mechanisms, comparable in effect to sucralose.

Aspartame (NutraSweet, Equal)

Among the most extensively studied sweeteners, it has the least concerning acute metabolic profile in RCT data. The Suez et al. 2022 Cell RCT found aspartame produced less pronounced microbiome and glycemic effects than saccharin or sucralose.

The 2023 International Agency for Research on Cancer (IARC) Group 2B “possibly carcinogenic” classification reflects limited human evidence and has not changed the safety positions of the FDA or EFSA. EFSA’s comprehensive risk assessment concluded aspartame does not pose a cancer risk at current intake levels.

One critical warning for Phenylketonurics: CONTAINS PHENYLALANINE. Phenylketonuria (PKU) is a rare genetic disorder in which the body cannot metabolize phenylalanine.

Acesulfame-K (Ace-K, Sweet One, Sunett)

It appears in combination with aspartame or sucralose in the majority of products where it is present, used to enhance sweetness while reducing aftertaste. It appears wherever aspartame or sucralose appear, often without consumer awareness that a second sweetener is present.

Acesulfame-K is understudied as an isolated ingredient. Its effects at typical human consumption levels are less well characterized than the other sweeteners on this list, which is itself important given how widely it is consumed. Its co-use with sucralose in particular places it in the same products as the sweetener with the most concerning evidence profile.

Stevia (Truvia, PureVia)

It currently carries the most benign metabolic profile among commonly used sweeteners in the available evidence. The Suez et al. 2022 Cell RCT found stevia produced less pronounced microbiome and glycemic effects than saccharin or sucralose. A large multi-cohort study of 47,910 adults reviewed by Harrold JA et al. found stevia was not associated with obesity risk, unlike sucralose, saccharin, and aspartame, which showed positive associations (PMC, 2024).

The evidence base for stevia is smaller than for older sweeteners. Its benign profile is supported by available data, not established by the same volume of research.

Monk Fruit (Luo Han Guo, Monk Fruit in the Raw)

Monk fruit extract is increasingly present in premium and health-positioned products. The evidence base is limited compared to any of the above, but no significant adverse metabolic findings have emerged to date. It is currently considered alongside stevia as the least concerning option when a non-caloric sweetener is being used.

The Sweetener Hierarchy: Current Evidence Summary

Based on the available evidence, from most to least metabolically concerning:

• Sucralose and saccharin: strongest microbiome disruption evidence and most consistent adverse effects on glycemic responses in RCT data

• Aspartame and acesulfame-K: mixed or limited evidence; aspartame less concerning in head-to-head RCT comparisons; acesulfame-K understudied in isolation

• Stevia and monk fruit: most benign profiles in currently available evidence

This hierarchy reflects the state of the science as of 2025-2026. The human evidence on appetite disruption across all sweetener types remains heterogeneous, and individual variation appears substantial. For a full discussion of the sweetener evidence and its implications for diet sodas, see the Diet Soda: Zero Calories, Not Zero Consequences article on The Metabolic Archives.

The Three Questions at the Shelf

Before anything goes in the cart, ask these in order.

One: Read the ingredient list, not the nutrition label. Are the first five ingredients things you would cook with?

Two: Do any of the worst offenders appear in those first five positions? HFCS or its aliases. Partially hydrogenated oils. Sugar as the first or second ingredient. Industrial emulsifiers. Artificial colors.

Three: How many ingredients are there in total? More than five or six begins to tell a story. A paragraph of ingredients tells the whole story.

For readers who want the complete label-reading methodology, the companion piece Do You Know The One Part of the Food Label That Actually Matters covers the full framework.

The Regulatory Landscape Is Shifting

In 2025, California signed the first law in the United States legally defining ultra-processed food and phasing out the most harmful additives from public school meals. The FDA announced plans in 2025 to phase out certain petroleum-derived artificial dyes from the US food supply. In early 2026, San Francisco filed the first government lawsuit against major UPF producers. The 2025 Lancet Series on Ultra-Processed Foods, authored by 43 international experts, called for stronger regulatory action. Legislators in dozens of US states have introduced or passed bills targeting harmful chemicals in the food supply.

When governments begin to act, the science has typically reached the threshold where the evidence is no longer deniable. You are learning to read a label in a moment when regulators are arriving at the same conclusions.

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

This series has examined every major participant in the American healthcare system. Each has been held accountable in proportion to their contribution to what American healthcare has become. One participant has not been examined yet: the patient.

Intellectual honesty and scientific rigor demands we take a look to every player on the system, and that includes the patients. Before you turn the anger against me, I ask you to evaluate the arguments and evidence presented herein with an open mind and be willing to accept we, as the users of the system, share some portion of the responsibility as well.

The Copay Is Not the Price

Employer-sponsored insurance covered approximately 159 million Americans in 2023. The average employer contribution to family coverage was $16,357 annually or roughly 73% of the total premium (KFF Employer Health Benefits Survey, 2023). Medicare and Medicaid together covered approximately 140 million Americans at a combined federal and state expenditure exceeding $1.5 trillion annually (CMS National Health Expenditure Data, 2023).

The person who believes the copay is their entire financial participation in the healthcare transaction is mistaken. They are paying for everyone else’s avoidable consumption, and everyone else is paying for theirs in return.

When Patients Ask For That They Do Not Need

Approximately 30% of all outpatient antibiotic prescriptions, 47 million annually, are unnecessary, written primarily for viral respiratory ailments (Fleming-Dutra KE et al., JAMA, 2016). Sinusitis is the single diagnosis generating the most antibiotic prescriptions in American outpatient medicine: 56 per 1,000 population annually. Inappropriate prescribing for sinusitis and pharyngitis alone cost the privately insured system $69 million in excess spending in a single study year (Pew Charitable Trusts, 2023). The ultimate consequence is 2 million antibiotic-resistant infections and 23,000 deaths annually at a system cost of $30 billion (CDC, Antibiotic Resistance Threats, 2019).

Direct-to-consumer pharmaceutical advertising influences patient behavior as well. It encourage patients on stable treatment to ask (in some cases demand) a switch to a newer, heavily marketed equivalent with no demonstrated clinical superiority. The cost difference falls on the insurer and ultimately on all premium payers.

Physician shopping, seeking additional opinions until the desired outcome is obtained, compounds both problems. It circumvents the clinical judgment the system depends on, generates costs at every consultation, and creates a documented market incentive for the physician willing to provide the desired answer. This does not apply to patients rightfully seeking second opinions for serious or unexpected conditions, those are legitimate and most competent physicians will encourage them.

The professional consequence for the physician who fails to comply is swift. The patient leaves, posts a negative review, and usually transfers care to a physician who will comply. This ends penalizing the original physician’s clinical integrity, while financially incentivizing unprofessional behavior.

If you enjoy evidence-based medical information, subscribe to receive these articles delivered to your mailbox every week.

Subscribe now

Brand Name Over Generic

Generic drugs are required by the FDA to be bioequivalent to their brand name counterparts: identical in active ingredient, dosage form, route of administration, strength, and therapeutic effect. A review of bioequivalence data from more than 2,000 FDA-approved clinical pharmacokinetic trials found no significant difference in therapeutic effect between branded and generic drugs (Califf RM et al., PMC5417581). Generics cost approximately 80 to 85% less than their brand name equivalents. Between 2009 and 2019, generic drug use saved the US healthcare system nearly $2 trillion (FDA, Generic Drugs: Questions and Answers).

Despite this, more than one-third of patients report a preference for branded products over generics, and 46% have asked their physician to prescribe a brand name drug over an available generic alternative (Shrank WH et al., PMC1852907). Patient requests for brand name drugs over generically equivalent alternatives cost the Medicare Part D program $673 million in 2017 alone, and cost Medicare patients themselves an additional $109 million in unnecessary out-of-pocket spending in the same year (Bai G et al., JAMA Network Open, 2021). Across the entire healthcare system, unnecessary brand name dispensing when generic equivalents are available generates an estimated $8.8 billion in excess expenditure annually.

The Motorized Scooter Bubble

Medicare covers power wheelchairs and motorized scooters as durable medical equipment for beneficiaries with documented severe mobility impairment who cannot operate a manual wheelchair. The Scooter Store, the largest power wheelchair supplier with approximately 80% of its revenue derived from Medicare patients, launched a television campaign in late 1990s and 2000s telling elderly viewers they needed a power scooter to live an independent life, they were entitled to one, and Medicare would pay for it. This campaign created a growing demand from medicare beneficiaries seeking their own motorized scooter benefits from physicians oftentimes without identifiable medical need.

Physician who found no qualifying mobility impairment were positioned by the company as the obstacle, fostering an adversarial relationship between patient and physician. Former Scooter Store employees testified that the company ranked physicians by their willingness to prescribe and operated programs specifically designed to pressure physicians who had declined to certify patients as qualifying (DePaul Journal of Health Care Law; Washington Post, August 2014).

The Department of Health and Human Services Inspector General found that 80% of Medicare payments for power wheelchairs industry-wide were made in error, the majority to people who did not need the equipment or lacked documentation of need (HHS OIG Report OEI-03-02-00600, 2004). Since 1999, Medicare made more than $8 billion in payments for 2.7 million wheelchairs and scooters. The prescription rate for power wheelchairs increased 33-fold between 1994 and 2001 — a trajectory tracking precisely with the expansion of direct-to-consumer durable medical equipment advertising during the same period (Kessler D et al., PMC1850931). The government was aware of the fraud pattern as early as 1998 and did not act substantively until 2003 to 2004.

When Patients Stop Treatment

Medication non-adherence costs the US healthcare system between $100 billion and $300 billion annually in avoidable spending (Iuga AO, McGuire MJ, Risk Management and Healthcare Policy, 2014; Cutler RL et al., BMJ Open, 2018). It is associated with 125,000 preventable deaths annually and accounts for up to 25% of hospitalizations (Bosworth HB et al., Duke Health, 2018).

A portion of non-adherence episodes are attributable to populations at significant socioeconomic disadvantage making it often impossible to maintain medical compliance. While they do contribute to the figures cited above, their lack of medical compliance is certainly non-malicious. A different group of patients are willfully non-compliant, seeking care and stopping it for no excusable reasons. In my experience the latter group is significantly smaller, but no official numbers to distinguish these populations are available for review.

The well defined consequences from patient non-adherence are quality penalties and negative readmission metrics that fall on physicians and institutions alike. The Hospital Readmissions Reduction Program penalizes hospitals for readmissions without adjustment for whether the patient discharged against medical advice, stopped their medications the day after discharge, or returned directly to the lifestyle that produced the original admission.

What Patients Do Not Change

Chronic diseases consume approximately 90% of the nation’s $4.9 trillion annual healthcare spending (CDC, Fast Facts, 2025). The majority are significantly preventable or modifiable through behavioral change.

The specific cost figures:

• Smoking-related disease exceeds $240 billion.

• Obesity costs the healthcare system approximately $173 billion annually (Biener A et al., Health Affairs, 2010).

• Physical inactivity costs $192 billion (NHLBI, 2019).

• Poor diet accounts for approximately $50 billion in cardiometabolic disease costs (Pearson-Stuttard J et al., PLOS Medicine, 2019).

I acknowledge behavioral change is difficult, and socioeconomic conditions make it more difficult for some more than others. However it does not change what the behaviors cost society at large.

The physician who has repeated the goals-of-care conversation, adjusted medications to accommodate behaviors that do not change, ordered tests required by progressive deterioration, often find the patient and family attribute the lack of improvement to inadequate medical care instead.

What Families Do

End-of-life care (depending on how end-of-life is defined) consumes approximately 25% of all Medicare spending (Riley GF, Lubitz JD, Health Services Research, 2010; Aldridge MD, Kelley AS, American Journal of Public Health, 2015). The median Medicare expenditure in the last six months of life exceeds $28,000 per beneficiary. This is exacerbated by families that, purely out of grief, request every available life-sustaining intervention for patients with terminal diagnoses and no realistic prognosis for recovery. While I don’t condemn their motivations, their actions do contribute to the increasing financial stress of our healthcare system.

On the other hand, I have directly experienced families that actively undermine inpatient care by delivering contraband; the most common being food and cigarettes, although in rare instances, it can also include alcohol and even street drugs. Whether this stems from misguided love or loyalty, this behavior directly prevents the clinical outcomes the care team is being held accountable for producing, often leading to prolonged hospital stays with the increased costs and penalties already discussed elsewhere.

What Patients Do Not Disclose

Dietary supplements generate approximately 23,000 emergency department visits and 2,000 hospitalizations annually in the United States, based on nationally representative surveillance data from 63 emergency departments collected between 2004 and 2013 (Geller AI et al., NEJM, 2015). Disclosure rates for supplement use to treating physicians are estimated at 25 to 33% (Awortwe C et al., Frontiers in Pharmacology, 2025).

The problem here is not the patient decision to use a supplement, is the undisclosed supplement use along with prescription medications.

A patient on warfarin or a direct oral anticoagulant using a supplement with known antiplatelet or anticoagulant properties — Ginkgo biloba, fish oil at high doses, vitamin E, nattokinase — without disclosing it, is unknowingly creating a bleeding risk. The resulting hemorrhagic event requires hospital care for management of both the bleeding and associated complications. That episode was preventable by a single conversation that did not happen.

The Honest Close

This series demands addressing the public conversation society avoids. Patients are participants in the system, and participation carries rights and responsibilities.

Our healthcare system has an obligation to every patient regardless of the choices they make. That obligation is not conditional on behavior and it should not be. Healthcare resources are finite, that is an unavoidable fact. If we want the resources to meet the needs of society we need to hold all parties equally accountable for the efficient allocations of such resources.

One of those parties, is the patient.

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

What Ultra-Processed Food Is

The accepted scientific standard is the NOVA classification system, developed by Carlos Monteiro at the University of Sao Paulo in 2009 and adopted by the UN Food and Agriculture Organization as its preferred framework for dietary analysis. NOVA divides food into four groups based on the extent and purpose of processing.

• Group 1 is unprocessed or minimally processed food: vegetables, fruit, meat, fish, eggs, plain grains, legumes.

• Group 2 is processed culinary ingredients: oils, flours, salt, sugar: things used to prepare food at home.

• Group 3 is processed food: canned fish, cured meats, simple cheeses, fermented foods: recognizable ingredients combined in recognizable ways.

• Group 4 is ultra-processed food.

NOVA Group 4 products are industrial formulations manufactured primarily from substances extracted or derived from food: refined starches, hydrogenated oils, protein isolates, high-fructose corn syrup. These are combined with additives not found in any home kitchen: emulsifiers, artificial flavors, colorants, humectants, anti-caking agents, preservatives.

They are designed for palatability, shelf stability, and profit, not nourishment.

A useful field test: read the ingredient list. If it contains substances you would not find in a kitchen or if the list runs longer than a paragraph, you are almost certainly looking at a Group 4 product.

How We Got Here

In the 1950s and 1960s, two competing hypotheses existed for the dietary driver of coronary heart disease. John Yudkin, a British physiologist, identified added sugars. Ancel Keys, an American physiologist, identified dietary fat. What resolved the debate was not science, was money.

The Sugar Research Foundation identified an existential commercial threat in Yudkin’s work. Internal documents later obtained by researchers at UCSF showed that the Foundation recognized as early as 1954 that a low-fat dietary environment would increase per-capita sugar consumption by more than one third.

The Foundation funded Harvard nutrition researchers in the mid-1960s to produce a literature review on dietary fat and coronary heart disease. The result was published in the New England Journal of Medicine in 1967 without disclosure of industry funding, a standard that did not yet exist. The review dismissed Yudkin’s sugar hypothesis and elevated Keys’s fat hypothesis.

A 2016 analysis of the Sugar Research Foundation’s own internal correspondence, published in JAMA Internal Medicine by Kearns, Schmidt, and Glantz, documented this sequence with primary source evidence. The scientific consensus that emerged from the 1960s and 1970s reflected what the industry had paid to produce.

The 1977 Policy Moment

The Senate Select Committee on Nutrition and Human Needs, chaired by Senator George McGovern, issued Dietary Goals for the United States in January 1977. The goals recommended reducing fat, cholesterol, and refined sugars while increasing complex carbohydrates and fiber. Three of eight senators on the committee dissented, arguing the evidence more strongly implicated refined carbohydrates than fat.

The food industry faced an immediate commercial problem. Fat provides palatability, texture, mouthfeel, and satiety; remove it and the product fails on the shelf. The solution was systematic substitutions. Sugar was added to restore taste, salt was increased to restore flavor, partially hydrogenated vegetable oils (trans-fats) were expanded to restore texture and extend shelf life. A growing toolkit of industrial additives restored the sensory qualities that whole-food fat had provided naturally.

The Low-Fat Era in a Single Product

No product illustrates the period more clearly than margarine.

Margarine was originally introduced in the nineteenth century as a cheap butter substitute for military and lower-income populations. By the 1980s, it had been rebranded as the heart-healthy alternative to saturated animal fat. It contained no cholesterol, medical societies endorsed it, a public primed to fear butter adopted it widely.

The mechanism that made liquid vegetable oil semi-solid at room temperature was partial hydrogenation: the industrial introduction of hydrogen bonds into unsaturated fatty acid chains. Partial hydrogenation produces trans-fatty acids as a byproduct. Trans fats raise LDL cholesterol, lower HDL cholesterol, and promote systemic inflammation.

A 2006 review in the New England Journal of Medicine by Mozaffarian and colleagues estimated that trans fat consumption was responsible for up to one in five myocardial infarctions per year in the United States. The FDA banned partially hydrogenated oils from the food supply in 2018, nearly four decades after margarine’s heart-healthy marketing era began.

Modern margarines have replaced partial hydrogenation with inter-esterification: a different chemical rearrangement of fatty acids on the glycerol backbone that achieves comparable physical properties without producing the same trans-fat profile. Animal data has demonstrated glucose intolerance and insulin resistance with inter-esterified fat consumption. A 2016 review by Mensink and colleagues in Advances in Nutrition concluded that the potential metabolic health risk of long term inter-esterified fat human consumption warrants serious concern.

The Obesity Timeline

The national obesity rate in the United States was approximately 13–14% through the mid-1970s (CDC NHANES data). The rise began between 1976 and 1980, coinciding precisely with the low-fat mandate’s translation into the documented rise in UPF consumption tracked in NHANES surveys. The largest increases through the 1980s and 1990s were in sugar-sweetened beverages, salty snacks, refined grain products, and fast food. By 2022, the adult obesity rate had reached 41.9%.

If you enjoy evidence-based medical information, subscribe to receive these articles delivered to your mailbox every week.

Subscribe now

What the Industry Knew

Ultra-processed food was not accidentally engineered to override appetite. The peer-reviewed evidence establishes that it was deliberately engineered using strategies directly imported from tobacco science.

Beginning in 1963, major tobacco companies began acquiring large segments of the US food industry. R.J. Reynolds and Philip Morris eventually owned brands including Del Monte, Nabisco, General Foods, Kraft, and 7UP. Peer-reviewed research published in Obesity in 2019 by Fazzino and colleagues, using the public tobacco industry archive, found that foods owned by tobacco companies between 1988 and 2001 were 29% more likely to be classified as fat-and-sodium hyperpalatable and 80% more likely to be classified as carbohydrate-and-sodium hyperpalatable than foods produced by non-tobacco-owned companies during the same period.

A 2026 review in the Milbank Quarterly, authored by researchers from Harvard, Duke, and the University of Michigan, concluded that ultra-processed foods are not simply natural products but highly engineered delivery systems designed specifically to maximize biological and psychological reinforcement and habitual overuse, sharing key engineering strategies with the tobacco industry including dose optimization and hedonic manipulation (Gearhardt, Brownell, and Brandt, 2026).

Industry trade publications in their own words described the goal as “turning consumer cravings into commercial wins” and acknowledged that “for decades, indulgence has been the profit engine.”

With US, UK, and EU markets saturated, the industry pushed into South America, Africa, Eastern Europe, China, and India. According to the November 2025 Lancet Series on Ultra-Processed Foods, authored by 43 international experts, UPF consumption has doubled in Brazil, Canada, and Mexico and tripled in China, South Korea, and Spain within a period of a few years. More than 50% of the $2.9 trillion distributed to food corporation shareholders between 1962 and 2021 was paid out by UPF manufacturers alone.

What Processing Does to Food

Before examining what ultra-processed food does to your body is worth examining what industrial processing does to food itself.

Food matrix destruction. Whole food has physical structure: fiber networks, cell walls, the spatial arrangement of macronutrients within intact cellular architecture. That structure governs digestion rate, glucose release kinetics, and the gut-brain satiety signaling that tells you when to stop eating. Industrial processing destroys it. The result is food that is digested faster, absorbed more rapidly, produces sharper glycemic excursions with corresponding insulin responses, and fails to engage the satiety mechanisms that intact food reliably triggers.

Refined fat, sugar, and salt at non-natural concentrations. The combinations of fat, sugar, and salt found in ultra-processed products are calibrated to maximize hedonic response and drive consumption beyond what your satiety system would otherwise permit. The reward pathway engagement produced by these combinations exceeds what any whole food can generate.

Industrial additives. Emulsifiers, artificial sweeteners, preservatives, colorants, and flavor enhancers serve industrial functions: shelf stability, texture restoration, appearance, and palatability amplification. They are not in your food to nourish you. Several additives have documented effects on gut microbiome composition and intestinal barrier integrity independent of their caloric content.

What Ultra-Processed Food Does to Your Body

Gut microbiome disruption. Ultra-processed food is deficient in dietary fiber, the primary substrate for beneficial gut bacteria, and rich in refined sugars, artificial sweeteners, and emulsifiers that directly alter microbial composition. Higher UPF consumption is associated with decreased microbial diversity, depletion of beneficial species including Akkermansia muciniphila and Faecalibacterium prausnitzii, increased pro-inflammatory microorganisms, elevated intestinal permeability, and systemic endotoxemia via lipopolysaccharide translocation, all of which propagate the chronic low-grade inflammation that sustains and advances insulin resistance (Zinöcker and Lindseth, 2018; Nutrients, 2025).

Disrupted appetite and satiety signaling. The Hall randomized controlled trial, published in Cell Metabolism in 2019, is the only inpatient RCT that has directly tested whether UPF drives overconsumption independently of nutrient content. Twenty adults were randomized to two-week periods of ultra-processed or unprocessed diets matched for presented calories, energy density, sugar, fat, fiber, and macronutrient composition. Ad libitum intake was approximately 500 kcal per day higher on the ultra-processed diet. Body weight changes tracked directly with caloric intake differences. The only variable that differed between conditions was the degree of processing. This is proof-of-concept evidence from a controlled experiment: small sample size (n=20), short duration (two weeks), primarily younger adults.

Addictive overconsumption. Hyperpalatable ultra-processed food engages the brain’s reward system in ways that structurally parallel addictive substances: rapid delivery of reinforcing stimuli, short-lived reward driving repeated consumption, tolerance effects requiring increasing quantity to achieve the same hedonic response. The published addiction science literature now explicitly frames UPF as addictive.

Displacement. Approximately 70% of packaged food on US grocery shelves is ultra-processed. Americans overall derive 55% of their daily calories from UPF. Children derive 61.9%, with children aged 6–11 at 64.8% the highest intake of any age group (CDC Data Brief No. 536, August 2025, NHANES 2021–2023). The fiber, phytonutrients, intact food matrix, and prebiotic substrates of whole food are simply absent from the diet.

The epidemiological evidence. A systematic review and meta-analysis of 207,291 participants across seven prospective cohort studies found UPF consumption associated with a 21% increased risk of all-cause mortality, a 50% increased risk of cardiovascular disease mortality, and a 66% increased risk of heart disease mortality. Separate meta-analyses found UPF consumption associated with a 15–53% higher risk of developing type 2 diabetes and a significantly elevated risk of metabolic syndrome across cross-sectional and cohort study designs. All large-scale outcome evidence is strictly observational.

Your First Step Out

The rest of this series will address dietary patterns in detail. For now, three simple substitutions to start with today.

Instant mashed potatoes, replaced by potatoes. The food matrix remains intact, industrial starch, flavoring agents, emulsifiers, and sodium phosphates in the packet are gone.

Instant oatmeal, replaced by old-fashioned or steel-cut oats. Instant oats are pre-cooked and rolled thin to accelerate cooking and digestion. Steel-cut oats require 20 minutes; old-fashioned rolled oats require five. Add your favorite natural flavoring yourself.

Flavored fruit yogurt, replaced by plain Greek yogurt with fresh or frozen fruit. A standard flavored yogurt contains 12–20 grams of added sugar per serving. Plain Greek yogurt contains none, and the fruit you add provides the food matrix that the fruit puree concentrate in the cup has already destroyed.

These substitutions are meant as illustrative examples of how you can start moving away from UPF. Each one reduces your daily UPF exposure, preserves food matrix, and consume food your biology was originally built to process.

That is how lifestyle modification works: not a complete overhaul in one day, instead one substitution at a time, sustained over months and years.

On future articles in the series we visit diet modification in detail, for now cutting back on ultra-processed foods is the first strategy you can start implementing today.

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

This piece is an account of decades spent inside the profession witnessing our collective failures. This indictment is self-inclusive, treated with the same intellectually honest standard I have strived for elsewhere.

Nothing that follows changes a fundamental truth: the majority of physicians entered medicine to serve patients and continue doing so despite increasing constraint, diminishing authority, and mounting personal cost. It provides accountability the profession at large.

The Original Sin

Cost-plus reimbursement, the dominant payment model through much of the postwar period, rewarded volume, duration, and expenditure without reference to outcome. A portion of the profession responded with excess: extended hospital stays, procedures without clear indications, frequency of follow-up appointments for stable conditions. The payment reforms that followed were institutional responses to physician-driven cost inflation.

Cesarean Section Explosion

The cesarean section rate climbed from approximately 5% in 1970 to over 32% today. The mechanism is documented in peer-reviewed literature: when fertility declined through the 1970s and early 1980s, reducing obstetricians’ volume of vaginal deliveries, cesarean rates increased in direct proportion. A nationally representative dataset shows a strong within-state correlation between fertility decline and cesarean rate increase during this period, consistent with an induced demand model (Gruber and Owings, RAND Journal of Economics, 1996). Women delivering at hospitals generating higher profit per cesarean procedure were significantly more likely to undergo cesarean delivery than women at lower-profit hospitals (JAMA Network Open, 2021, PMC7980096).

The American College of Obstetricians and Gynecologists has itself stated that the rapid increase in cesarean rates without concomitant improvement in maternal or neonatal outcomes raises significant concern about cesarean delivery overuse.

Multiple drivers beyond profit operate simultaneously: liability fear, patient preference, scheduling convenience.

If you enjoy evidence-based medical information, subscribe to receive these articles delivered to your mailbox every week.

Subscribe now

The Reactive Response

When reimbursement model changed, the profession adapted. The RVU architecture undervalued primary care rewarding procedures instead. The response in many practices was to compress encounter time and increase daily patient throughput. This “assembly-line” practice was a choice made by physicians responding to financial pressures.

The consequence for patients was abbreviated encounters with reduced depth of clinical engagement, and the erosion of the therapeutic relationship.

The Ownership Conflict

Other practices adopted a different model in response to the financial pressures.

Physician ownership of ancillary services creates a direct and financial conflict of interest. The physician who owns in-house laboratory equipment, imaging technology, stress testing facilities, DEXA scan units, or ECG and X-ray equipment has a financial incentive to order more of these services. Physician-owned facilities order significantly more ancillary services than non-physician-owned ones for identical patient populations (Medicare Payment Advisory Commission, MedPAC, 2005; Iglehart, New England Journal of Medicine, 2005).

The federal government recognized this conflict of interest as consequential enough to require legislative response. The Stark Law was the result: it prohibits physician self-referrals for Medicare and Medicaid designated health services.

As a result other arrangements were developed for continued capture of economic benefits from self-referral while technically complying with the law. Some of those include: management services organizations, indirect compensation arrangements, and space and equipment rental structures. Those represent legally creative efforts pushing the limits of the law.

Defensive Medicine Costs

The threat of liability for failing to order a test, to refer, or to pursue an intervention a patient demanded, contribute to measurable costs increases through over utilization.

The most conservative peer-reviewed estimate puts defensive medicine costs at approximately $46 billion annually, representing roughly 2.9% of total healthcare spending at the time of measurement (Mello et al., Health Affairs, 2010). Nine out of ten physicians in a national survey reported practicing defensive medicine (Jackson Healthcare, 2010). In a Massachusetts study of internists, 27% of CT scans, 16% of laboratory tests, and 14% of hospital admissions were reported as ordered due to concerns about liability rather than clinical indication (BMJ Quality and Safety, 2014, PMC4231873).

Defensive medicine takes two forms:

• Assurance behavior: ordering additional services to document clinical thoroughness and reduce liability exposure. I admit being guilty of this practice.

• Avoidance behavior: declining high-risk procedures or clinical situations where liability exposure is elevated, producing access problems in obstetrics, neurosurgery, and emergency medicine.

Fragmentation as Professional Culture

The expansion of subspecialty referral has contributed to patient care fragmentation. The drivers are multiple: liability fear, the RVU undervaluation of primary care work, time pressure, and, in some cases, the financial architecture of referral relationships within physician networks.

The result: complex patient accumulates multiple specialists, medication lists grow, testing is duplicated across specialties with no coordinating clinician tracking the entire picture.

The Continued Medical Education Industry

Approximately 28,000 to 46,000 active peer-reviewed medical journals now exist worldwide. Collectively they publish between 1.8 and 3 million articles annually. PubMed adds approximately 800,000 to 1 million new citations per year. A physician attempting to maintain current knowledge across even a single specialty would need to read dozens of relevant articles daily, across hundreds of distinct journals.

Many busy physicians, myself included, depend on formal CME programs and digest publications to maintain professional competency. Many of these are partially or totally funded by device manufacturers, pharmaceutical companies or healthcare systems. They usually concentrate on education promoting drugs over non-financially viable treatments, and limit discussion of emerging non-commercial alternatives. They drive physician behavior and become the basis for the accepted standards of care that effectively govern the practice of medicine.

CME industry sponsorship accounts for approximately 50–65% of total CME revenue in the United States, representing more than $1 billion annually from pharmaceutical and device manufacturers (Lexchin, Canadian Family Physician, 2006, PMC2231419; Lexchin and Sekeres, Canadian Family Physician, 2014, PMC4131951). The industry estimates it recoups $3.56 in increased sales for every dollar invested in CME.

Sponsored CME increases prescribing rates for the sponsoring company’s products. In one analysis, positive clinical effects of the sponsoring drug were mentioned 2.5 to 3 times more often than competitor drugs during sponsored educational sessions (Bowman and Pearle, Journal of Continuing Education in the Health Professions, 1988). Physicians who interact more frequently with industry sponsored CME have poorer prescribing habits and lower rates of evidence-based guideline adherence (Avorn and Shostack, Circulation, 2010).

The Case of Oxycontin

Between 1996 and 2002, Purdue Pharma sponsored more than 20,000 educational programs disseminating information that misrepresented OxyContin’s addiction risk. These programs were funded by the pharmaceutical company, led by industry-sponsored physicians, and accredited by professional bodies. OxyContin sales grew from $48 million in 1996 to $1.1 billion in 2000.

The educational programs were a covert promotional strategy, the epidemic that followed was the public health consequence.

Accountability Without Absolution

The majority of physicians choose medicine to serve patients despite existing systemic limitations. Nothing in this piece is meant to diminish the genuine dedication and sacrifices most of them bring to patient care.

Is meant as an intellectually honest acknowledgment of the profession’s failures, as well as my own. A well overdue reckoning of our collective participation in the healthcare system’s failures.

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

It took me years to realize that what we doctors take for granted is knowledge many patients lack. Is the knowledge we often fail to share wrongly assuming some universal understanding. That finally ends here.

In this multipart series we will explore in detail what lifestyle modification means, why it is important and how to implement it in your daily life.

What Is Lifestyle Modification

Lifestyle modification is a structured, evidence-based therapeutic intervention built on four specific pillars: diet, exercise, stress reduction, and sleep hygiene. Each pillar has a defined evidence base, a set of practical behaviors, and a measurable biological effect. Each will receive its own dedicated installment in this series.

Modification is the important qualifier here. It doesn’t mean uprooting all your routines and adopting some foreign lifestyle. It means gradually implementing moderate and sustainable changes over time. The combination of small sustained behavioral modifications produce significant results on your overall metabolic health.

If you enjoy evidence-based medical information, subscribe to receive these articles delivered to your mailbox every week.

Subscribe now

How Metabolic Disease Begins

Modern lifestyle patterns of caloric excess, physical inactivity, chronic psychological stress, and disrupted sleep, drive the accumulation of visceral fat, the metabolically active adipose tissue that sits deep in the abdominal cavity around the organs. As visceral fat expands, it delivers increasing levels of free fatty acids and inflammatory compounds directly to the liver through the portal circulation. The liver gradually becomes resistant to insulin’s signals, hepatic insulin resistance propagates outward: the pancreas compensates by producing more insulin, peripheral tissues gradually stop responding, and the entire system begins operating under conditions of chronic metabolic stress (Bergman, 2006; Jensen, 2006; Griffith et al., 2010).

This cascade produces a cluster of findings that clinicians call metabolic syndrome: elevated fasting glucose, abdominal obesity, high triglycerides, low HDL cholesterol, and elevated blood pressure.

The Logic of the Treatment

Specific lifestyle behaviors initiated this process, so modifying those behaviors is the most important intervention available. Medications are often needed to address the consequences but lifestyle modification remains the primary therapy.

A 2025 systematic review and meta-analysis in eClinicalMedicine quantified metabolic rebound following GLP-1 receptor agonist discontinuation across multiple trials. In SURMOUNT-4, more than half of weight loss achieved with tirzepatide rebounded over 52 weeks after stopping the drug, accompanied by deterioration of glycemic control and reversal of lipid and blood pressure improvements. Participants who maintained behavioral changes after discontinuation preserved their metabolic gains; those who did not, relapsed.

What the Science Shows

The strongest evidence for lifestyle modification as a disease-modifying intervention comes from the Diabetes Prevention Program and its long-term follow-up study, the DPPOS. The DPP enrolled over 3,000 high-risk individuals and demonstrated that intensive lifestyle intervention reduced progression to type 2 diabetes by 58% compared to placebo, outperforming metformin, which achieved a 31% reduction over the same period (Diabetes Prevention Program Research Group, 2015).

The most recent high-quality randomized controlled trial with metabolic syndrome remission as its explicit primary endpoint is the ELM trial, published in JAMA Internal Medicine in November 2025. Researchers randomized 618 participants with metabolic syndrome across five U.S. sites to either a structured, habit-based lifestyle intervention or enhanced standard care. The intervention consisted of 19 small group sessions over six months, targeting four specific daily behaviors. At 24 months, sustained metabolic syndrome remission was significantly higher in the intervention group: 27.8% versus 21.2%, an adjusted odds ratio of 1.46 (Powell et al., 2025).

The four behaviors targeted in the ELM intervention were:

• Eating vegetables at every meal

• Brisk walking

• Sensory awareness: the deliberate practice of noticing hunger, fullness, stress, and fatigue before acting on automatic responses

• Emotion regulation: recognizing and managing the emotional drivers that push toward disordered eating and sedentary behavior

The step count data from the ELM trial makes the most important point directly. Participants in the intervention group averaged 4,823 daily steps versus 4,158 in the comparator group. The difference associated with metabolic syndrome remission was approximately 665 steps per day, sustained at 24 months (Powell et al., 2025).

The majority of participants in the ELM intervention group did not achieve full metabolic syndrome remission, and the trial’s authors acknowledged that targeting lifestyle alone may limit the ceiling of effect.

What Is Coming

This series will cover each pillar of lifestyle modification in dedicated installments:

• Diet — the evidence on what to eat, meal architecture, and why the timing of eating matters as much as its content.

• Exercise — how physical activity modifies insulin resistance directly, and what “enough” actually looks like.

• Stress — the cortisol-visceral fat axis, and why stress management is a metabolic intervention, not a wellness add-on.

• Sleep — how sleep disruption drives metabolic dysfunction, and what the evidence supports for recovery.

Each installment will be specific, practical, and grounded in the same evidence standard applied here. The goal is to give you the specific changes you need to adopt as part of the overall intervention.

The next article will cover ultra-processed foods and how they affect your metabolic health.

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

You walk into the hospital lobby and see it behind the counter: America’s Top 100 Hospital for Cardiac Care. A warm sense of reassurance fills you up knowing this is the right hospital for your mother’s cardiac event. You head to the elevators leaving any lingering doubts behind.

The Accreditation Industry: Scale and Structure

The Joint Commission is the dominant accrediting body in American healthcare. It accredits approximately 80% of the nation’s hospitals and accredits or certifies more than 22,000 healthcare organizations and programs in total (The Joint Commission, jointcommission.org). A majority of state governments recognize Joint Commission accreditation as a condition of licensure for Medicare and Medicaid reimbursement.

Hospitals pay the Joint Commission approximately $37,000 to $46,000 annually to maintain accreditation status, plus separate survey fees during inspection years. The Joint Commission’s accreditation division reported $164 million in revenue in 2016. It is a not-for-profit organization in legal structure. In economic function, it operates as a mandatory vendor to an industry that cannot afford to lose its product (GAO-07-79, 2007).

The Inspection Process: Policy and Practice

The Joint Commission’s official position is that hospitals receive no advance notice of survey dates. Surveys have been formally designated as unannounced since January 1, 2006, following sustained public criticism of the prior practice of notifying hospitals in advance. A 2005 Washington Post investigation found that approximately 99% of inspected hospitals were accredited, and that serious problems in care delivery were sometimes overlooked or missed. The Boston Globe documented that the Joint Commission’s governing board had long been dominated by representatives of the industries it inspects, an observation the organization has never disputed.

The Joint Commission publishes a comprehensive Survey Activity Guide that outlines in precise detail what surveyors will examine. Surveys occur within a known 18-to-39-month window following the previous survey. The practical result is an institutional preparation culture: policies get reviewed, signage gets updated documentation backlogs get addressed, staff get reminded of procedures they are expected to demonstrate. The period before a Joint Commission survey has a specific texture in hospital practice that differs from the period after one.

During my years in practice at times I was explicitly informed, weeks before a scheduled Joint Commission survey, that specific patient charts were selected for inspector review and documentation on those charts required attention before the survey took place. I offer this as my own experience, not as institutional policy. I leave the gap between those two things for the reader to assess.

What the Evidence Says About Accreditation and Patient Outcomes

A 2018 observational study published in the BMJ examined more than 4.2 million Medicare patients admitted to 4,400 hospitals between 2014 and 2017 (Lam MB et al., BMJ, 2018). The findings: no significant difference in risk-adjusted 30-day mortality or readmission rates between Joint Commission-accredited hospitals and hospitals reviewed through state-based systems.

Another systematic review covering two decades of accreditation research found a trend toward positive associations between accreditation and clinical outcomes but characterized the methodological quality of included studies as variable and the evidence as insufficient for definitive conclusions (Brubakk K et al., BMC Health Services Research, 2015). A 2025 systematic review of Joint Commission International accreditation concluded that whether accreditation adds genuine value “remains unclear” (PLOS One, 2025).

What accreditation does appear to improve consistently is process compliance and documentation quality. A 2018 cross-sectional study examining the evidence base for Joint Commission standards found that a substantial proportion of accreditation requirements were supported by low-quality evidence, expert opinion and case reports rather than controlled trials (Hatcher JH et al., BMJ Open, 2018).

If you enjoy evidence-based medical information, subscribe to receive these articles delivered to your mailbox every week.

Subscribe now

The Conflict at the Center

The Joint Commission operates a consulting subsidiary called Joint Commission Resources, which reported $63.5 million in revenue in 2016. Joint Commission Resources sells preparation services, educational materials, and consulting support to healthcare organizations, many of which are also accreditation clients of the Joint Commission itself. The organization maintains formal firewall policies prohibiting shared information between its accreditation and consulting arms.

The Centers for Medicare and Medicaid Services found the concern serious enough to open a formal inquiry and solicit public comment on whether accrediting organizations providing fee-based consulting to the facilities they accredit constitutes a conflict of interest (Modern Healthcare, December 2018).

That inquiry produced no formal regulatory action, the business arrangement remains in place.

Board Certification: The Original Promise and What It Became

The American Board of Medical Specialties, founded in 1933, built a credentialing system around a premise: a standardized examination to establish that physicians achieved a minimum level of knowledge in their field. A systematic review of studies from 1966 to 1999 found that 16 of 29 analyses showed a statistically significant positive association between board certification and better clinical outcomes but 13 did not (Tamblyn R et al., Academic Medicine, 2002).

The Maintenance of Certification program was introduced in 2000 and expanded in 2014. MOC requires board-certified physicians to pay for additional ongoing testing, and practice improvement activities to maintain their certification or potentially loss hospital privileges and insurance panel participation in many systems. The ABMS currently certifies approximately 989,000 physicians. Combined revenue across its 24 member boards is estimated at $350 million annually (Coronis Health, 2020; Medical Economics, 2024).

A published financial analysis confirmed that the majority of member boards increased revenue substantially following MOC implementation (Hawkins RE et al., Journal of Continuing Education in the Health Professions, 2015). The American Board of Anesthesiology stated publicly in 2011 that MOC requirements “will not have a sufficient impact on patient care.” No high-quality evidence has since established that MOC participation improves patient outcomes.

Antitrust litigation has been filed against multiple ABMS member boards by the Practicing Physicians of America, alleging that tying MOC to initial board certification and hospital credentialing violates federal antitrust law. The Pennsylvania Medical Society adopted a formal vote of no confidence against the American Board of Internal Medicine in 2016. Surveys of practicing physicians consistently find that the majority view MOC as financially motivated, marginally relevant to daily practice, and a significant driver of burnout and early retirement.

Hospital Rankings: The Mathematics of the Lobby Wall

The US News Best Hospitals rankings evaluate more than 4,500 hospitals annually across 16 specialty categories, plus state rankings, metro rankings, best children’s hospital rankings, and procedure and condition ratings. The arithmetic of overlapping regional and specialty categories makes it structurally possible for a very large proportion of American hospitals to appear on some ranking in some category.

San Francisco City Attorney David Chiu formally demanded that US News disclose payments received from the hospitals it ranks including licensing fees for the Best Hospitals badge, subscriptions to its Hospital Data Insights platform, and advertising revenue from its rankings publications arguing that failure to disclose these financial relationships violated Federal Trade Commission regulations (Becker’s Hospital Review, 2023). US News acknowledges it receives revenue from hospitals it ranks, but maintains that this revenue does not influence rankings.

Penn Medicine’s University of Pennsylvania Health System withdrew from the rankings in 2023, with its CEO citing a methodology that focuses excessively on inpatient care, relies on Medicare data covering only patients 65 and older, and creates perverse incentives for hospitals to invest mostly in ranking categories. St. Luke’s University Health Network withdrew citing the use of subjective physician peer opinion surveys which function, as one health quality expert described it, as a popularity contest rife with economic and referral-relationship biases (Healthcare Finance News, 2023).

In some specialties, US News rankings are based entirely on peer opinion surveys. The organization has acknowledged this limitation and indicated its intention to phase out peer opinion as objective outcome data becomes available across more domains.

The “Top Physician” Industry: A Documented Racket

In 2019, ProPublica investigative journalist Marshall Allen received a solicitation for a Top Doctor award. He disclosed to the sales representative that he was not a physician but the award remained available. The customized plaque — cherrywood with gold trim or black with chrome — was offered at standard pricing (Allen M, ProPublica, 2019; Reader’s Digest, October 2019).

The Consumers’ Research Council of America’s Top Physicians database, as documented by ABC News, included a cardiologist convicted of manslaughter for administering a lethal propofol overdose to a patient, and a pediatrician convicted of molesting more than 100 children. Both remained listed as top physicians in their specialties (ABC News, 2012).

Cooper Health System issued a formal written warning to its physicians identifying specific soliciting organizations by name and instructing staff that any award offer requiring payment for a plaque or listing was likely a scam (Cooper Health System internal communication, 2018).

Some slightly better physician recognition programs use nomination-based processes with license and discipline verification. Castle Connolly’s co-founder acknowledged it would be “very difficult” to prevent gaming of the nomination process. Super Doctors explicitly disclaims that listed physicians are not necessarily better than non-listed physicians. They are still peer-reputation surveys with documented susceptibility to referral relationship and economic biases.

What the Certification Industry Gets Right

Baseline accreditation standards do maintain a process compliance floor that has genuine value. Hospitals operating below that floor are more dangerous. The requirement to maintain medication management systems, infection control protocols, and staff competency documentation produces real institutional discipline. The original board certification examination established a minimum knowledge standard that served a legitimate gatekeeping function. Some of the evidence on certification and clinical outcomes is positive.

The problem is that they have been marketed to patients making decisions about where to seek care and which physicians.

The better questions when evaluating a hospital or physician:

• What are the documented complication rates for the specific procedure you need?

• What is the volume of that procedure at this institution?

• Is this physician in good standing with their state medical board?

These are publicly available through state licensing databases, CMS Hospital Compare, and the ABMS physician lookup tool. They are harder to find than a lobby poster. They are more informative.

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

What is GMO Foods?

“GMO” is a label applied to a production method, not to a substance or an ingredient.

The category includes at least four distinct approaches. Transgenic modification inserts DNA from one species into another, the original and most contentious form. Cisgenic modification transfers genetic material between organisms of the same species, using molecular tools to accomplish what conventional cross-breeding does through repeated generations. Gene editing makes targeted changes to an organism’s existing DNA without inserting foreign material. Biofortification engineers crops to produce higher levels of nutrients they would otherwise contain in insufficient quantities.

It’s also worth noting that humanity has been deliberately manipulating plant genetics since agriculture began. Grafting was practiced in China and the Mediterranean more than two thousand years ago. The goal was always the same: combine desirable traits from different genetic sources into a single cultivated plant. What genetic engineering adds is molecular precision.

Why GMO Crops Exist

Yield improvement is frequently cited as the primary driver of GMO development, and it’s the easiest target for critics. The more complete picture is considerably more interesting.

Pest and disease resistance was among the earliest and most consequential applications. Crops engineered to produce Bacillus thuringiensis (Bt) toxins dramatically reduced crop loss to insect damage, and with it, the volume of broad-spectrum insecticides applied to food crops. A 2014 meta-analysis of 147 studies in PLOS ONE by Klümper and Qaim found that GMO crop adoption had on average reduced chemical pesticide use by 37% and increased yields by 22%, with farmer profits rising by 68%, gains concentrated in Bt crops and developing-world contexts with high pest pressure.

Insect damage creates entry points for fungal infection, and fungal infection produces mycotoxins, compounds with established carcinogenic and hepatotoxic properties. A meta-analysis of 21 years of field data by Pellegrino et al. in Scientific Reports (2018) found that Bt maize showed mycotoxin levels 28.8% lower, fumonisin levels 30.6% lower, and trichothecene levels 36.5% lower than conventional maize. If you are concerned about cancer risk from food, the evidence suggests Bt maize is the safer option.

Drought tolerance and post-harvest loss reduction address the agricultural realities of climate instability and food insecurity in lower-income countries. And then there is biofortification, specifically Golden Rice.

Golden Rice was engineered to produce beta-carotene, which the body converts to vitamin A, in a grain that hundreds of millions of people in South and Southeast Asia depend on as a dietary staple. Vitamin A deficiency is associated with an estimated 4,500 preventable child deaths daily and is the leading preventable cause of childhood blindness globally. A clinical trial by Tang et al. in the American Journal of Clinical Nutrition (2009) found that a single cup of Golden Rice can supply approximately 50% of the recommended daily intake of vitamin A. The bioavailability evidence is solid; the mortality extrapolation is reasonable but remains indirect.

Golden Rice has been actively opposed for decades by many of the same organizations that frame their advocacy as protecting human health. Some of that opposition reflects legitimate concerns about corporate control of food systems in vulnerable populations. But the scientific basis for opposing the crop itself is not there.

If you enjoy evidence-based medical information, subscribe to receive these articles delivered to your mailbox every week.

Subscribe now

What the Health Evidence Actually Shows

Three decades of research encompassing more than 3,000 peer-reviewed studies and the formal consensus positions of every major independent scientific and public health body globally, find no consistent causal link between GMO food consumption and cancer, reproductive toxicity, allergic disease, or chronic illness.

The National Academies of Sciences (NAS) report, Genetically Engineered Crops: Experiences and Prospects (2016), is among the most comprehensive independent reviews ever conducted on a food technology question. A comprehensive review published in GM Crops & Food (2022) by Brookes and Barfoot, examining environmental and pesticide-related outcomes of GMO crop adoption from 1996 to 2020, similarly found no consistent evidence of harm to human health.

The European Union has been institutionally skeptical of GMO technology maintaining import restrictions and cultivation moratoriums that the scientific evidence has never justified. More than 130 independent research projects, involving over 500 research groups across more than 25 years and funded entirely by the European Commission, reached the same conclusion as every other major body: GMO crops are no more risky than those produced by conventional plant breeding. The European Commission published a summary of this program in 2010 as A Decade of EU-funded GMO Research, with subsequent EU Framework Programme funding extending the work.

The Study That Shaped a Generation of Fear

In 2012 a French molecular biologist named Gilles-Eric Séralini, published a paper in Food and Chemical Toxicology claiming that rats fed GMO maize developed tumors at dramatically elevated rates. The paper was accompanied by a coordinated media campaign, a book, a documentary, and graphic photographs of tumor-bearing animals. The political response was immediate: France’s prime minister called for a European ban, Russia suspended GMO maize imports, and Kenya banned GMO crop cultivation entirely. Then the science was examined.

The rat strain used, Sprague-Dawley, develops spontaneous tumors in up to 80% of animals by the end of a normal lifespan, making it a poor model for tumor causation studies. The sample sizes were inadequate for the statistical claims made. There was no dose-response relationship, a basic requirement for establishing biological causation. European Food Safety Authority (EFSA) issued a statement within weeks of publication declaring that the study did not meet acceptable scientific standards. The journal retracted the paper in November 2013, without the author’s consent, citing fundamental methodological failure. Séralini subsequently republished in a lower-tier journal; the republication addressed none of the substantive criticisms.

The pattern is not unique. Andrew Wakefield published a fraudulent case series in The Lancet in 1998 claiming a link between the measles-mumps-rubella (MMR) vaccine and autism. The paper was retracted; Wakefield was stripped of his medical license; the methodology was demonstrated to be fabricated. Measles outbreaks have continued in populations that absorbed the fear and never absorbed the correction.

The Concerns That Are Real

Herbicide-resistant weeds are a documented and growing problem. The International Survey of Herbicide Resistant Weeds has recorded 59 weed species that have developed resistance to glyphosate since 1996. Herbicide sales in Canada increased 270% between 1994 and 2023 following GMO crop introduction, according to the Canadian Biotechnology Action Network.

Biodiversity loss and soil microbiome disruption are associated with the agricultural practices that accompany large-scale GMO deployment. But here is the distinction the public conversation almost never makes: they are consequences of monoculture industrial agriculture misusing a powerful tool, not consequences of the tool itself.

The Irish potato famine of 1845 killed approximately one million people and drove another million into emigration; it resulted from the catastrophic vulnerability of a genetically uniform monoculture. One pathogen, Phytophthora infestans, swept through a crop with no genetic diversity to resist it. The vulnerability was created by industrial-scale cultivation of a single genetic variety, which is exactly what produces the ecological risks associated with GMO crops today. This problem predates GMO technology by a century.

Corporate consolidation of the seed market is a separate concern. Following the Bayer-Monsanto merger, Bayer controls an estimated 35% of the global corn seed market, 28% of soybean seed, and 70% of cottonseed, according to the National Sustainable Agriculture Coalition. USDA analysis has documented concerns about intellectual property concentration limiting farmer seed-saving rights. It is an economic and political question, however, not a food safety question.

Letting the Evidence Speak

You came to this piece with one question: are GMO foods bad for you?

The evidence now available to answer it spans 30 years, more than 3,000 peer-reviewed studies, and the independent scientific consensus of institutions on multiple continents, including institutions with every institutional incentive to find a problem if one existed.

The health fears are not supported by the evidence. Ecological concerns are real, but not arguments against genetic engineering itself. Corporate consolidation concern is legitimate, but is a market structure problem, not a health related concern.

And yet the most consequential applications of this technology are the ones that receive the least attention in a debate shaped almost entirely by the concerns of people who are not food insecure.

Now you have the evidence, but only you can answer the question: are GMO foods bad for you?

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

A study published in Nature Metabolism in May 2026 offers the most rigorous human evidence to date that the gut microbiome the vast community of bacteria living in your digestive tract is part of the answer (Olsson et al., Nature Metabolism 8, 1212–1228, 2026).

Two Different Surgeries

To understand the findings, it helps to know that the two most common bariatric procedures are anatomically quite different.

Roux-en-Y gastric bypass (RYGB) is a major rearrangement of the digestive tract. The stomach is divided into a small pouch, and the small intestine is rerouted so that food bypasses most of the stomach and the upper portion of the small intestine entirely. Sleeve gastrectomy (SG) is a simpler procedure: roughly 80% of the stomach is removed, leaving a narrow tube, but the intestines remain anatomically intact.

The Oseberg Study

The Olsson et al. study is a subanalysis of the Oseberg randomized controlled trial (RCT), conducted in Norway. Seventy-seven patients with obesity and T2D were randomized to either RYGB or SG. Before surgery and again at 12 months, researchers collected stool samples and analyzed the gut microbiome using whole-genome sequencing, which reads the genetic material of the entire microbial community rather than sampling a subset of species. Five-year remission outcome data were also available for analysis.

At 12 months, T2D remission rates were 74% for RYGB versus 52% for SG, a statistically significant difference (logistic regression, P=0.046). RYGB also produced greater weight loss, larger reductions in fasting blood glucose, and stronger post-meal glucagon-like peptide 1 (GLP-1) responses.

RYGB produced larger and more consistent shifts in gut microbial composition across patients accounting for 5.3% of gut microbiota compositional variation, compared with 1.9% for SG. The more extensive anatomical rearrangement of RYGB appears to produce a more forceful, uniform remodeling of the gut microbial environment.

What Remission Looks Like in the Microbiome

Patients who achieved T2D remission showed a distinct microbial profile compared to those who did not.

Remitters had significantly greater increases in bacterial gene richness: a measure of the diversity and functional capacity of the microbial community. Higher gene richness has been linked to better metabolic health in previous research, and in this study the effect of remission status on gene richness increase was larger than the effect of surgery type. The specific bacteria most strongly associated with remission included Alistipes species, Lachnospira eligens, and uncharacterized members of the Christensenellales order.

Butyrate is a beneficial compound produced when gut bacteria break down certain dietary fibers and amino acids. It supports insulin secretion, reduces intestinal inflammation, and helps regulate gut hormone release. A specific gene, ato, which encodes a key step in the lysine-to-butyrate conversion pathway, increased in abundance after surgery exclusively in patients who achieved remission and this was true across both surgery types, independent of how much weight was lost.

The Weight-Independence Finding

The microbiome changes associated with remission were not simply a reflection of losing more weight. After statistical adjustment for degree of weight loss, the association between microbial shifts and remission remained significant (R²=0.03, P=0.001 for surgery type effect after weight-loss adjustment).

Weight loss clearly contributes to T2D remission after bariatric surgery. What this study adds is evidence that the gut microbiome appears to contribute through separate, additional mechanisms. Patients with favorable microbiome shifts also showed better GLP-1 responses and improved beta-cell glucose sensitivity, suggesting a microbiome-to-incretin axis that operates alongside the metabolic effects of weight reduction.

SG produces more variable microbiome shifts between individuals than RYGB does, it creates a natural range of microbial outcomes to examine. In SG patients, the magnitude of microbiome change correlated positively with GLP-1 levels, beta-cell function, and 5-year remission status offering a cleaner window into the relationship between microbial shift and metabolic outcome than the more uniform RYGB response allows.

A Counterintuitive Finding About Butyrate Levels

Despite the increased bacterial capacity to produce butyrate and other short-chain fatty acids (SCFAs) after surgery, measured fecal concentrations of these compounds actually decreased at 12 months. The decrease in propionate and butyrate was driven specifically by the remission group.

The authors’ interpretation: the gut is not producing less butyrate, it is absorbing and using it more efficiently. Think of it this way: if a factory’s output is rising but the warehouse is consistently empty, the goods are being shipped out and used as fast as they are made. Whether that interpretation is correct requires dedicated flux studies. For now, the finding stands as a plausible hypothesis, not an established mechanism.

Could the Microbiome Predict Who Benefits?

A machine-learning analysis using pre-surgical microbiome data found that baseline abundances of Lachnospira eligens, Alistipes senegalensis, Christensenella minuta, and butyrate production genes (ato, 4hbt, buk) were predictive of 5-year T2D remission status. This raises an intriguing possibility: that microbiome profiling before surgery could eventually identify patients most likely to achieve durable remission and guide clinical decision-making.

The modeling was performed on a small sample using XGBoost, a machine-learning method that requires prospective validation in much larger cohorts before any clinical application could be considered. The bacteria identified are not yet fully characterized, and several are not yet reliably isolatable in the laboratory. The authors are appropriately cautious, describing them as candidates for future study rather than therapeutic targets.

Prior Evidence and the Causal Question

This study adds to a growing body of evidence. A 2022 study by Debédat et al. in Gut Microbes followed 100 RYGB patients for five years and found that unresolved T2D was associated with pre-surgical enrichment in specific Bacteroidia species, including Bacteroides fragilis and Phocaeicola dorei (Debédat et al., Gut Microbes 14(1):2050635, 2022). Critically, when stool from poor-outcome human donors was transplanted into germ-free mice, the animals developed impaired glucose tolerance and insulin resistance independent of body weight raising the possibility that the microbiome differences are not just correlating with poor outcomes but contributing to them.

Cross-species translation from mouse models to humans is not straightforward, and the mechanism by which the transplanted microbiome impaired glucose tolerance was not established. The Olsson et al. study does not resolve the causal question in humans all microbiome-remission associations in this paper are correlational.

Limitations

The sample is small: 77 patients across two surgical groups. Metformin use could not be controlled for because it covaried too strongly with remission status in this cohort. Metformin has well-documented independent effects on gut microbial composition, making it impossible to fully separate the surgery’s microbiome effects from the drug’s. Individual effect sizes for microbiome parameters were modest, and the causal chain from microbial shift to metabolic improvement has not been established in humans.

None of these limitations undermine the value of the findings. An RCT design with whole-genome microbiome sequencing, weight-loss-adjusted analysis, and five-year clinical follow-up is a methodological standard that previous work in this area has rarely reached.

What It Means

Bariatric surgery does not work by restricting calories alone. The gut microbial community is being remodeled by these procedures, and that remodeling appears to contribute to whether a patient achieves diabetes remission through mechanisms that extend beyond weight loss. The specific bacteria and metabolic pathways identified here are now candidate targets for microbiome-based interventions: therapeutic probiotics, dietary strategies, or other approaches that might one day replicate or enhance the metabolic benefits of surgery without the surgery itself.

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

The Metabolic Archives is for educational and informational purposes only, and is not intended as medical advice, diagnosis, or treatment, and does not constitute a doctor-patient relationship. Do not adopt any recommendation discussed in any article or guides published here, make changes or abandon any prescribed medical treatment without prior consultation with your physician. Always seek the advice of your physician or other qualified health provider for any questions regarding your medical condition and recommended treatment options.

By reading this post, you acknowledge that you have read and agree to the Terms of Service of The Metabolic Archives, which govern all use of this content including restrictions on reproduction.

© 2026 The Metabolic Archives. All rights reserved.

Tags: bariatric surgery, gut microbiome, type 2 diabetes, diabetes remission, metabolic health, obesity medicine, short-chain fatty acids, science news

Who decide which medications your insurance covers? Who decide what you pay at the pharmacy counter? Who decide which pharmacy you can use without paying a penalty? Not your physician, insurer or drug manufacturer.

It is an entity called a Pharmacy Benefit Manager. The invisible middle man of America’s healthcare system.

The Invisible Hand

Three companies control approximately 80% of prescription benefit management (PBM) in the United States: CVS Caremark, Cigna’s Express Scripts, and UnitedHealth Group’s OptumRx. Together they administer drug benefits for roughly 270 million Americans in a market worth nearly $600 billion annually (Federal Trade Commission, September 2024). These are among the largest corporations in the country.

Your employer or insurer contracts with a PBM to manage the prescription drug benefit on their behalf. The PBM then contracts with drug manufacturers to negotiate rebates, contracts with pharmacies to set reimbursement terms, and administers the benefit for every covered member. It sits at the center of every transaction without being visible in any of them.

What PBMs Actually Do

Claims processing at scale: Approximately 4 billion prescription drug transactions occur annually in the United States (Commonwealth Fund, March 2025). Each requires real-time eligibility verification, formulary checking, drug utilization review, prior authorization adjudication, copay calculation, and payment processing across thousands of health plans, tens of thousands of pharmacies, and hundreds of drug manufacturers simultaneously.

Pharmacy network contracting: Negotiating reimbursement terms with tens of thousands of pharmacies nationally is beyond the capacity of any individual health plan. The aggregated purchasing power of a PBM representing 270 million covered lives produces negotiating leverage. In principle, this should reduce costs.

Drug utilization review: Real-time checking of prescriptions for drug-drug interactions, duplicate therapy, dosing errors, and therapeutic alternatives at the point of dispensing catches errors that would otherwise reach patients.

Formulary development: Health plans lack the clinical infrastructure to independently evaluate thousands of drugs across hundreds of therapeutic categories. PBMs employ pharmacy and therapeutics (P&T) committees to perform this evaluation and determine which drugs are covered, at what tier, and under what conditions.

If you enjoy evidence-based medical information, subscribe to receive these articles delivered to your mailbox every week.

Subscribe now

Evidence shows that members with pharmaceutical companies relations seating in P&T committees are more likely to request formulary additions of those companies’ drugs (Friesen et al., Journal of Clinical Pharmacy and Therapeutics, 2020). Today CMS requires at least one independent practicing physician and one independent practicing pharmacist free of financial conflicts on these committees (AMCP Partnership Forum, Journal of Managed Care and Specialty Pharmacy, 2023). Only two members without ties to the industry on a committee usually including twenty or more.

How PBMs Make Money

Rebate Retention and the List Price Inflation Cycle

Drug manufacturers pay PBMs rebates in exchange for preferred formulary placement. The rebate is calculated as a percentage of the drug’s list price. The higher the drug’s list price, the larger the rebate the PBM receives. The PBM therefore has a financial incentive to favor drugs with higher list prices over therapeutically equivalent alternatives with lower list prices and smaller rebates.

Manufacturers inflate list prices specifically to fund the rebates PBMs demand for formulary placement. The patient’s copay, deductible, and coinsurance is calculated against the full list price, not the net price after rebate, inflating the patient’s out pocket expenses accordingly. The PBM excludes lower-cost alternatives from the formulary, because a lower list price generates a smaller rebate reducing PBM revenue.

Spread Pricing

For generic drugs, PBMs are reimbursed by health plans and employers at one price and pay pharmacies at a lower price: this difference is retained as profit. The spread is pure margin extracted from the drug transaction with no corresponding service delivered (FTC Interim Report, July 2024; Commonwealth Fund, March 2025).

Vertical Integration

The three largest PBMs are owned by or affiliated with a major health insurer and simultaneously owns its own pharmacy chain. CVS owns Caremark the PBM, Aetna the insurer, and CVS the pharmacy chain. UnitedHealth owns OptumRx the PBM and operates extensive healthcare provider networks. Cigna owns Express Scripts the PBM (FTC, September 2024).

The PBM steers prescriptions to its own pharmacy, charges its own insurer the spread and structures formularies to maximize rebate magnitude. A 2025 study found clear evidence: the share of prescriptions filled at PBM-owned pharmacies was substantially higher among patients enrolled in PBM-owned health plans than among patients covered by other insurers (CSG South, December 2025).

Vertical integration also produces another casualty: the independent community pharmacy. PBMs reimburse their own affiliated chain pharmacies at higher rates than independent pharmacies for identical drugs. Some PBMs exclude independent pharmacies from plan networks entirely. The independent pharmacist is being driven out of business by a reimbursement structure the PBM controls.

The Insulin Case

In 1999, the average list price of Eli Lilly’s Humalog insulin was $21. By 2017, it had risen to more than $274, over 1,200% increase (Feldman and Rome, JAMA Network Open, 2023). The production cost for Humalog did not significantly increase during the same period.

The Federal Trade Commission’s administrative complaint, filed September 2024, documents the mechanism. The three largest PBMs pushed insulin manufacturers to compete for preferred formulary coverage based on the size of rebates rather than net price. Manufacturers raised list prices to fund those rebates while PBMs collected billions in rebates and fees. When lower-cost insulin alternatives became available, PBMs systematically excluded them from formularies.

From 2012 to 2019, gross sales for four leading insulin products more than doubled, from $13 billion to $27 billion. Net sales after rebates dropped approximately 40%, from $8 billion to $5 billion. By 2019, the rebates paid exceeded 80% of list price (FTC Administrative Complaint, September 2024). By 2019, one in four insulin-dependent patients in the United States was unable to afford their medication (Fang and Selvin, JAMA, 2023).

In February 2026, the FTC secured a landmark settlement with Express Scripts: it requires separating PBM compensation from list prices, patient out-of-pocket expenses calculated from net prices without rebates, and increased transparency projected to reduce patient out-of-pocket costs for drugs like insulin by up to $7 billion over ten years (FTC, February 13, 2026).

Litigation against CVS Caremark and OptumRx continues. The PBMs have simultaneously filed suit against the FTC challenging its administrative proceedings on constitutional grounds.

What Is Currently Being Done

The FTC’s two-year investigation produced an interim report in July 2024, an administrative complaint against all three major PBMs in September 2024, and the February 2026 Express Scripts settlement. PBM reform is one of the rare legislative territories where Democrats and Republicans have found common cause without giving in to lobbying pressure. State attorney general actions have proceeded in Vermont, California, Kentucky, Ohio, and Hawaii. Federal legislation passed in 2025 requires PBM compensation delinking from drug list prices and mandatory rebate pass-through for Medicare Part D beginning January 1, 2028 (KFF, February 2026; AJMC, March 2026).

The legislation addresses Medicare Part D specifically. The commercial employer market covering approximately 159 million Americans has weaker protections under current law (KFF, February 2026).

What This Means for You

The PBM system was created to solve administrative coordination of prescription drug benefits at national scale but evolved into a mechanism for extracting value from the drug transaction at the patient’s expense. Always in the dark.

You cannot demand accountability from a system you cannot see.

Now you finally can!

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

What Galectin-3 Actually Does

Galectin-3 is a beta-galactoside-binding lectin, a protein that attaches to specific sugar structures on the surface of cells and in the spaces between them. It performs legitimate functions in wound healing, immune activation, and normal tissue repair; the problem is what it does when those processes go wrong.

In cancer biology, galectin-3 is upregulated across multiple tumor types and has well-characterized roles in tumor cell aggregation, adhesion to the extracellular matrix, resistance to programmed cell death (apoptosis), angiogenesis, and evasion of immune surveillance (Glinsky and Raz, Carbohydr Res. 2009;344(14):1788-91).

In fibrotic disease, galectin-3 drives macrophage polarization toward a profibrotic phenotype and promotes the activation of myofibroblasts, the cells responsible for pathological collagen deposition in the liver, lung, and kidney (Glinsky and Raz, 2009).

In cardiovascular disease, elevated circulating galectin-3 is associated with adverse outcomes in heart failure, and the U.S. Food and Drug Administration (FDA) has cleared galectin-3 as a biomarker for heart failure risk stratification.

What MCP Is and How It Gets There

Native citrus pectin is a high-molecular-weight polysaccharide. The modification process uses controlled heat and alkaline pH to reduce molecular weight and degree of esterification, generating shorter galactan chain fragments with improved bioavailability (Leclere et al., Front Pharmacol. 2013;4:128).

Some of those fragments do reach the bloodstream after oral dosing. However the pharmacokinetic questions, and the data required to answer them has not been generated to any rigorous standard. The available pharmacokinetic literature is predominantly produced by or associated with manufacturers of MCP products, uses proxy measures rather than direct tissue concentration assays, and has not been independently replicated (Leclere et al., 2013).

Before any MCP fragment reaches the circulation, it passes through the gut microbiome, where bacteria ferment pectin and alter its molecular composition. The extent to which microbial fermentation changes the identity and activity of the circulating fragments varies between individuals and has not been characterized.

What the Wellness Industry Claims

The claims attached to MCP in the wellness and supplement space fall into several distinct categories.

Anti-cancer claims hold that MCP inhibits tumor metastasis, slows cancer progression, reverses immune evasion, and enhances the effectiveness of chemotherapy. Specific claims for prostate cancer invoke PSA (prostate-specific antigen) doubling time prolongation as evidence of anti-tumor activity. Anti-metastatic claims are made broadly across cancer types.

Antifibrotic claims hold that MCP reduces organ fibrosis in the liver and elsewhere, making it relevant for conditions including non-alcoholic fatty liver disease and metabolic dysfunction-associated steatohepatitis (MASH).

Cardiovascular claims hold that MCP lowers circulating galectin-3 levels and by extension reduces cardiovascular risk.

Heavy metal chelation claims hold that MCP binds heavy metals and facilitates their elimination from the body.

General immune modulation and anti-aging claims hold that MCP reduces systemic inflammation, combats “inflammaging,” and supports general immune function.

These claims are presented as established fact, often citing the same small set of studies repeatedly. What those studies actually show is a different matter.

What the Research Actually Shows

Cell Studies and Animal Models

The preclinical evidence for MCP is reasonably consistent. Cell line studies across prostate, breast, colon, bladder, ovarian, and melanoma models have demonstrated that MCP reduces tumor cell adhesion, invasion, and angiogenesis while increasing apoptosis (Glinsky and Raz, 2009; Hossein et al., Cancer Med. 2019;8(9):4315-29; Fang et al., Acta Pharmacol Sin. 2018;39(12):1885-93). Synergy with paclitaxel in ovarian cancer spheroids and with other chemotherapy agents in respective experimental systems has been reported. Animal models have extended these findings into living systems, showing reduced tumor growth and metastatic spread in rodent models.

The effects observed in cell culture were produced at concentrations that have not been demonstrated to be achievable in human plasma or target tissue after oral supplementation. The two findings exist in different evidentiary worlds, and the supplement industry routinely collapses that distinction. Animal-to-human translation in oncology also has a well-documented failure rate. Approximately 95% of drugs that demonstrate meaningful anticancer activity in rodent models fail to demonstrate benefit in human trials.

If you enjoy evidence-based medical information, subscribe to receive these articles delivered to your mailbox every week.

Subscribe now

Human Evidence: The Full Account

Prostate cancer. The most-cited human oncology study is a prospective phase II trial by Keizman et al. (Nutrients. 2021;13(12)) enrolling 60 patients with non-metastatic, biochemically relapsed prostate cancer. Patients received PectaSol-C at 4.8 grams three times daily for six months. The study reported prolongation of PSA doubling time in a proportion of patients.

Two problems: first, the study had no concurrent control arm. Historical controls were used for comparison, which introduces substantial confounding from patient selection, changes in background treatment patterns, and regression to the mean. Without randomization and a concurrent placebo group, the PSA doubling time changes observed cannot be attributed to MCP.

Second, PSA doubling time is a surveillance parameter, not a tumor activity measurement. It influences clinical decisions about when to intervene, but it does not directly measure tumor burden, metastatic potential, or disease progression. Using PSA doubling time prolongation in an uncontrolled study to support an anti-metastatic claim is measuring a variable that cannot answer the question being asked.

Advanced solid tumors. A 2007 prospective pilot study by Azemar et al. (Clinical Medicine Oncology. 2007;1:73-80) enrolled 49 patients with advanced, mixed solid tumor types. There was no randomization, no control arm, and no standardized endpoint definition. The study is hypothesis-generating at best but cannot support efficacy claims for any tumor type.

The unresolved phase III trial. A phase III trial (NCT01681823) was registered and apparently conducted. As of the time of this writing, no peer-reviewed outcome data has been published.

Cardiovascular biomarkers. The most credible human data in the MCP literature comes from a study by Lau et al. (JACC Basic Transl Sci. 2021;6(1):12-21) examining MCP in hypertensive patients. MCP was associated with reductions in circulating galectin-3 levels. This is the best human evidence available and it demonstrates a biomarker effect. Whether galectin-3 reduction through MCP supplementation translates into fewer cardiovascular events, reduced hospitalizations, or mortality benefit is entirely unknown.

The Funding Problem

EcoNugenics, the manufacturer of PectaSol-C, has financial involvement in a substantial proportion of the human clinical literature on MCP. Supplement research operates without the pre-registration requirements, protocol adherence mandates, and independent data monitoring obligations that apply to pharmaceutical trials. The evidence base and the commercial interest are not separate entities in this literature. That does not make the studies fabricated, but it is a material fact about how they should be weighted.

The Pharmaceutical Industry as Calibration

The most important context the supplement industry fails to mentions is this: the pharmaceutical industry has spent years developing purpose-built galectin-3 inhibitors with defined binding affinity, characterized pharmacokinetics, and known tissue concentrations. They are engineered small molecules and biologics designed specifically to inhibit galectin-3 at therapeutically relevant concentrations.

GB0139, an inhaled galectin-3 inhibitor developed by Galecto Biotech, was tested in a phase 2b randomized controlled trial (GALACTIC-1, NCT03832946) in 173 patients with idiopathic pulmonary fibrosis (IPF). The primary endpoint, reduced rate of decline in forced vital capacity (FVC), was not met. Serious adverse events occurred in 7.8% of the treatment group versus 1.4% in the placebo group. Development was discontinued in August 2023.

Belapectin, a galectin-3 inhibitor developed by Galectin Therapeutics, was tested in the NAVIGATE trial (NCT04365868), a 355-patient, randomized, double-blind, placebo-controlled trial conducted across 130 sites in 15 countries. The primary endpoint was prevention of new esophageal varices in patients with MASH cirrhosis. The primary endpoint was not met in the intent-to-treat population. A pre-specified per-protocol subgroup showed a 49% reduction in new varices; a U.S. subgroup showed a 68% reduction. Updated biomarker data presented at the American Association for the Study of Liver Diseases (AASLD) annual meeting in 2025 showed reductions in fibrosis markers Pro-C3, PRO-C4, and YKL-40, suggesting biological activity. Subgroup analyses from a failed primary endpoint trial, however, are hypothesis-generating and not confirmatory. Development is not over for belapectin, but has not yet demonstrated actual clinical benefit.

The relevant question for MCP is this: if purpose-engineered galectin-3 inhibitors administered at known concentrations through optimized delivery routes are struggling to demonstrate clinical benefit under rigorous trial conditions, what is the realistic expectation for an oral polysaccharide supplement with uncharacterized bioavailability?

Verdict by Claim Category

Anti-metastatic and anti-tumor claims. Not supported by human evidence. The preclinical data is consistent and biologically plausible. The human data consists of one uncontrolled phase II study in prostate cancer using a surrogate endpoint that cannot answer the metastatic question, one uncontrolled pilot in heterogeneous solid tumors, and a completed phase III trial without published results. No efficacy claim for cancer prevention, treatment, or metastasis inhibition is justified by this evidence base.

Chemotherapy synergy claims. Demonstrated in cell culture and animal models. Not evaluated in any adequately designed human trial. The claim is plausible but clinically unproven. There are also theoretical concerns about whether galectin-3 inhibition could interfere with immune-mediated tumor killing in the context of immunotherapy, which has not been studied.

Antifibrotic claims. Plausible, supported by animal data, and tested in the pharmaceutical pipeline through belapectin, which failed its primary endpoint. No adequate human evidence exists to support an antifibrotic claim for MCP supplementation.

Cardiovascular claims. The galectin-3 biomarker reduction observed by Lau et al. (2021) in hypertensive patients is the most credible human evidence in the MCP literature. A biomarker reduction is not a cardiovascular outcome, whether this translates into clinical benefit is unknown.

Heavy metal chelation claims. Dietary fiber can adsorb heavy metals within the gut lumen and reduce their absorption; a process of gut-lumen binding, not chelation. Once heavy metals are in systemic circulation and deposited in tissues, an oral polysaccharide fiber has no plausible mechanism to reach them. The term “chelation” implies systemic metal removal, which requires compounds capable of entering tissues and forming stable metal-ligand complexes for urinary excretion. Pectin is not such a compound.

Immune modulation and anti-aging claims. No adequate human evidence. Theoretical and speculative beyond the galectin-3 pathway.

The consistent pattern across all claim categories is the same: the gap between cellular mechanics and clinical proof has not been closed, and the evidence required to close it has not been generated.

Where That Leaves You

MCP is not a proven treatment for cancer, fibrosis, cardiovascular disease, or heavy metal toxicity. The standard of evidence required to recommend it as a treatment has not been met. The desire for additional promising treatment is understandable and legitimate. What you deserve is an accurate account so that your decisions are based on evidence rather than on unproven claims.

If you are considering MCP, a few things are worth knowing. Its short-term safety profile at typical supplement doses is acceptable, however the drug interaction profile is real. MCP can impair absorption of tetracyclines, digoxin, thyroid hormones, and mineral supplements, and should be separated from these by at least two hours. Any supplement use should be discussed with your treating physician, who can review your specific medication list and advise on timing.

MCP occupies a specific and honest position: a compound with interesting cellular mechanisms, a preclinical record worth taking seriously, a human evidence base that is small and methodologically inadequate, and an unresolved pharmacokinetic problem that sits at the center of every efficacy claim made about it. The pharmaceutical industry’s experience with purpose-built galectin-3 inhibitors is the most honest evidence available for what MCP can realistically be expected to do.

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

When a hospital discharges a patient to a skilled nursing facility, most believe they are moving to the next stage of care. What they are actually entering is a separate industry, with its own financial architecture, staffing constraints, coverage rules, and incentive structure.

Menu of Post-Hospital Care Options

Skilled Nursing Facilities (SNFs) provide 24-hour nursing care, medication management, wound care, IV therapy, and short-term rehabilitation following hospitalization. They are the primary Medicare post-acute care setting.

Long-Term Care Facilities offer residential care for patients who cannot safely live independently due to chronic illness, cognitive impairment, or functional limitation. Medicaid is the primary payer for long-term residents. These facilities are frequently co-located with SNF units which creates confusion about the level of care on any given floor.

Inpatient Rehabilitation Facilities (IRFs) provide hospital-level rehabilitation for patients who can tolerate a minimum of three hours of active therapy per day. They are physician-directed, more heavily staffed than SNFs, and subject to stricter admission criteria.

Long-Term Acute Care Hospitals (LTACHs) serve patients requiring prolonged acute-level care — ventilator weaning, complex wound management, medically complex conditions — who no longer need the resources of an acute hospital but are not yet stable enough for SNF placement. They are the most clinically capable step-down setting and the least commonly available.

Home Health Services deliver skilled nursing and therapy in the patient’s home. They are designed for patients who are medically stable, functionally capable of managing basic needs with intermittent support, and living in an environment adequate to receive care.

A $200 Billion Industry

The post-acute care market generated approximately $194 to $200 billion in revenue in 2024 and is projected to reach $290 billion by 2033 (Grand View Research, U.S. Skilled Nursing Facilities Market Industry Report, 2033; Future Market Insights, USA Skilled Nursing Facility Market 2025–2035). For-profit facilities now account for more than 70% of market share, driven by large corporate chains and private equity-backed operators.

What Private Equity Ownership Actually Produces

If you enjoy evidence-based medical information, subscribe to receive these articles delivered to your mailbox every week.

Subscribe now

Following private equity acquisition of nursing home facilities, mortality during the facility stay and the subsequent 90 days increased 10% relative to non-private equity owned facilities, according to Gupta et al. (NBER Working Paper 28474, 2021), an analysis of Medicare data covering more than 7 million patients between 2000 and 2017.

Patients with cognitive problems in private equity-owned facilities were 50% more likely to be placed on antipsychotic medication. This lead to billing increases of 19% per stay driven by declines in staffing hours.

A 2025 analysis by AARP Florida examining 156 nursing home facilities following private equity acquisition found staffing declined 13%, facilities rated one star by CMS doubled from 10% to 21%, and five-star facilities dropped from 28% to 14% (AARP Florida, Change of Ownership and Quality in Florida Nursing Homes, 2025).

What These Facilities Are Actually Staffed to Deliver

Care is usually delivered by certified nursing assistants (CNAs), whose training is typically just weeks, under the supervision of licensed practical nurses (LPNs). Registered nurse (RN) oversight until recently was required only eight hours per day under federal standards (NursingHome411.org, citing CMS Final Rule on Minimum Staffing Standards for Long-Term Care Facilities, 2024). The remaining sixteen hours of the day, RN-level clinical assessment was not federally required to be present.

Higher RN staffing levels are associated with fewer pressure ulcers, lower restraint use, decreased infection rates, reduced inappropriate antipsychotic prescribing, lower mortality, and fewer emergency department visits and re-hospitalizations, findings consistent across multiple independent studies spanning decades (Harrington C, et al., Appropriate Nurse Staffing Levels for US Nursing Homes, Health Services Research, 2020, PMC7328494).

April 2024 CMS issued a rule that would have required 24-hour RN presence seven days per week, a change estimated to save 13,000 lives annually. The financial cost of providing 24-hour RN coverage was estimated at approximately $349 million annually across all facilities. The American Health Care Association and LeadingAge (the primary lobbying bodies for the nursing home industry) challenged the rule in federal court and in December 2025 CMS rescinded the requirement, reinstating the eight-hour standard.

The Service Gap

According to a federal analysis by the Assistant Secretary for Planning and Evaluation at HHS, if quality-optimizing staffing thresholds were implemented, 97% of all nursing home facilities would fail to meet one or more standards. A separate methodology in the same analysis estimated that 91% of nursing homes have nursing assistant staffing below minimal necessary care levels (ASPE HHS, State-Initiated Nursing Home Nurse Staffing Ratios: Annotated Review of the Literature).

In most SNFs, attending physician presence is limited to brief periodic visits, weekly or less frequent. Day-to-day clinical management falls to nursing staff, with physician availability by telephone. When a patient deteriorates acutely, the pathway to clinical intervention is considerably slower and less reliable than in an acute hospital.

The gap between what patients believe these facilities provide and what most of them are actually staffed to deliver is substantial. The clinical failures that follow are a predictable outcome.

Medicare Coverage and The Observation Status Trap

Medicare Part A covers SNF care at 100% for days 1 through 20 following a qualifying inpatient hospital stay of at least three consecutive days. Days 21 through 100 require a daily patient co-payment currently exceeding $200 per day, a cost most patients cannot sustain without supplemental insurance. After day 100, Medicare coverage ends entirely (Centers for Medicare and Medicaid Services, Skilled Nursing Facility Care Coverage, medicare.gov).

Medicare classifies observation status as outpatient care. Time spent under observation does not count toward the three-day inpatient requirement. A patient can spend four days in a hospital bed and have zero qualifying inpatient days if the hospital classified their stay as observation status (Center for Medicare Advocacy, Repeal the 3-Day Hospital Stay Requirement, September 2025; Society of Hospital Medicine, Observation Status: Current Issues).

The physician’s admission decision can be overruled retroactively by the hospital’s Utilization Review Committee, applying CMS criteria, frequently without physician input. The patient discovers the coverage consequence at discharge and the financial consequence can amount to thousands of dollars per day out of pocket.

Observation status carries a documented disparate impact on the poorest Medicare beneficiaries (Medicare Rights Center, Medicare Hospital Outpatient and Observation Status: The Three-Day Stay Problem, 2023). Neither the 2013 Two-Midnight Rule nor the 2015 NOTICE Act has resolved the problem. The decision that determines coverage is administrative.

SNF Coverage Window as a Billing Target

Within the covered period, the facility’s financial interest runs against early discharge. Every covered day generates revenue, discharging a patient before coverage ends foregoes that revenue. The patient who generated revenue on day 99 is a financial liability on day 101. The discharge that follows is calendar-determined. The question asked is not if the patient can safely transition home, is if coverage has ended.

Medicare patients discharged to SNFs face a 25% likelihood of readmission or death within 30 days. In a review of 200 SNF discharges, 67% of readmissions were rated as potentially preventable, with patients reporting that inadequate SNF treatment contributed to their returns (Mack D, et al., Implementation of a Skilled Nursing Facility Readmission Review Process, BMJ Quality and Safety, 2018, PMC6069909). The 25% readmission and mortality figure is consistent across multiple national analyses.

The Rehabilitation Therapy Billing Problem

SNF Medicare reimbursement was historically tied to the volume of rehabilitation therapy provided. This created a financial incentive to maximize therapy billing regardless of whether the patient was appropriate for or benefiting from it. Multiple large SNF chains faced federal fraud investigations and settlements related to therapy billing practices.

In 2019, CMS implemented the Patient Driven Payment Model (PDPM), replacing therapy-volume-based reimbursement with a model based on patient clinical characteristics (CMS, Patient Driven Payment Model, Implementation Documentation, 2019).

Choosing a Facility Under Pressure

The CMS Five-Star quality rating system exists and is publicly available. Staffing levels by shift are publicly reported but not easily accessible by a family at bedside. Private equity ownership is not disclosed in any standard admission document. The discharge planner’s recommended facilities may reflect network affiliation or bed availability rather than clinical fit.

A Word on Home Health

Home health is designed for patients who are medically stable, functionally capable of managing basic needs with intermittent support, and living in a home environment adequate to receive care. It is not continuous care and is not a substitute for the clinical monitoring of a facility setting.

The administrative discharge from a SNF to home health at coverage end, frequently places patients in a home health setting they may not be ready for yet. Home health’s own limitations mean the gap between what the patient needs and what home health can provide can be significant. The patient’s family then becomes the de facto care provider for most needs.

The System Is Working as Designed

The failures documented here are the predictable consequences of a system whose financial architecture has been allowed to operate with minimal accountability for clinical outcomes. A nearly $200 billion industry dominated by large corporate chains and private equity operators is a system that has been optimized for a purpose other than patient recovery.

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

The Metabolic Archives is for educational and informational purposes only, and is not intended as medical advice, diagnosis, or treatment, and does not constitute a doctor-patient relationship. Do not adopt any recommendation discussed in any article or guides published here, make changes or abandon any prescribed medical treatment without prior consultation with your physician. Always seek the advice of your physician or other qualified health provider for any questions regarding your medical condition and recommended treatment options.

By reading this post, you acknowledge that you have read and agree to the Terms of Service of The Metabolic Archives, which govern all use of this content including restrictions on reproduction.

© 2026 The Metabolic Archives. All rights reserved.

Parts One through Four of this series gave you the mechanism. This last piece gives you what you can do about it.

Remission Is Real — and It Is Not a Cure

Remission from insulin resistance and type 2 diabetes means sustained normal metabolic function without pharmacotherapy. It is documented in randomized controlled trials. The DiRECT trial, published in The Lancet Diabetes & Endocrinology, found that approximately 36% of participants in an intensive lifestyle intervention maintained full T2DM remission at two years, without medication, through weight loss and ectopic fat reduction (Lean et al., 2019).

Continued remission requires commitment to lifelong maintenance of lifestyle changes. Remission and even reversibility are possible for most people, but the degree of reversibility is dictated by the amount of residual insulin secretory reserve at the time of intervention. The earlier in the process you choose to act the higher the chances of remission, or even full reversal, success.

Early diagnosis with aggressive intervention becomes the best strategy for anyone with risks factors such as: abnormal fasting glucose, obesity, arterial hypertension, elevated triglycerides and low HDL cholesterol levels.

The Lifestyle Disease Framing

Insulin resistance is, for most of us, a lifestyle disease. The initial triggering events are closely linked to sedentary lifestyle, excessive calorie consumption and a diet rich in ultra-processed foods (UPF). All of these are part of a lifestyle conducive to metabolic dysregulation and mostly within our control.

Personal agency is the literal mechanism of treatment. The changes that produced the disease are the changes that can reverse it, the power to change the trajectory is all yours.

The food environment you have been living in was specifically engineered to override satiety signaling. The built environment was designed for sedentary efficiency. Education to understand the connection of lifestyle with the medical consequences never happened.

Dietary Intervention — Principles Over Prescriptions

The Mediterranean, DASH, and Volumetric diets are evidence-validated frameworks to address metabolic dysregulation. The principles they share include more intake of vegetables, whole foods, protein, with less ultra-processed food, and refined carbohydrate. You do not need to abandon your food culture just to understand the basic principles and how to apply them to your life.

The full framework for sustainable dietary change is developed in You Don’t Need a Diet Plan, which you can find in the archive.

Ultra-processed food reduction is the single most impactful dietary shift available. A well-designed inpatient randomized controlled trial by Hall et al. (2019), published in Cell Metabolism, found that participants on an ultra-processed diet consumed approximately 500 additional kilocalories per day compared to those eating minimally processed food with identical macronutrient availability under ad libitum conditions.

Ultra-processed foods are intentionally engineered to override the satiety signaling that would otherwise regulate intake. Remove them, and appetite regulation partially restores itself. The label reading skills that help you identify ultra-processed food are covered in Do You Know The One Part of the Food Label That Actually Matters? A dedicated post on ultra-processed food is forthcoming.

Eating sequence is a zero-cost intervention with documented effect. Consuming protein and vegetables before starches at a mixed meal reduces postprandial glucose peak by approximately 29–37% and postprandial insulin by approximately 20–48% compared to carbohydrate-first consumption, with no change in what you eat (Shukla et al., 2015; Shukla et al., 2017). This is developed in full in You Don’t Need a Diet Plan.

Protein-rich breakfast addresses multiple problems simultaneously. The cortisol peak of the morning creates a glucose-permissive hormonal environment that amplifies the postprandial insulin response to a carbohydrate-heavy breakfast. Adding protein blunts that response, produces sustained satiety through the morning, and supports muscle protein synthesis during the anabolic window following overnight catabolism. It simultaneously serves postprandial glucose management and sarcopenia prevention.

The all too common American breakfast pattern — a high calorie, carbohydrate rich meal, or worse yet, no breakfast at all — is the worst way to start your day. Without fiber or protein to slow down gastric emptying or stimulate satiety mechanism, they lead to excess calorie intake, a large glucose / insulin post-prandial peak with rapid disposal of the carbohydrate load. This typically leads to the mid-morning crash usually addressed by consumption of even more carbohydrate rich snacks as a bridge to lunch.

Start adopting a good balanced breakfast with high quality proteins instead of a heavy carbohydrate load.

The Supplement Landscape

Supplement claims are not required to be proven before products reach market. The FDA does not evaluate supplements for efficacy, or even safety, before sale. When you see a claim on a label, there is no regulatory requirement that it be true.

The two questions that cut through the marketing: What does the evidence actually show? And what is the effect size compared to sustained lifestyle change? On that second question, no supplement currently available produces metabolic improvements matching while sustained lifestyle modification achieves.

The best-supported supplements are just useful adjuvants, not the magic solution for bad habits.

If you enjoy evidence-based medical information, subscribe to receive these articles delivered to your mailbox every week.

Subscribe now

Supplements with Genuine, Though Modest, Evidence

Berberine activates AMPK, the same energy-sensing enzyme activated by exercise and metformin, and produces modest but statistically significant glucose-lowering in multiple randomized controlled trials in T2DM and metabolic syndrome populations (Yin et al., 2008). The effect is very real but also modest, different from what social media currently claims.

The comparison between berberine and GLP-1 receptor agonists that circulates widely online is a misrepresentation. GLP-1 agonists operate through a completely different mechanism. Calling berberine “nature’s Ozempic” is like calling a bicycle “nature’s airplane” because both move you forward. The comparison is false.

Berberine is a potent inhibitor of CYP3A4, CYP2D6, and P-glycoprotein (Feng et al., 2019; Guo et al., 2012). These are the metabolic pathways responsible for clearing statins, warfarin, cyclosporine, certain antiarrhythmics, and certain antidepressants from your body. Inhibiting these pathways raises blood concentrations of those drugs, potentially to toxic levels. If you are on any prescription medication, you must discuss berberine with your physician before starting it.

Coenzyme Q10 (CoQ10) is an endogenous mitochondrial electron carrier whose synthesis shares the mevalonate pathway with cholesterol. Statin therapy inhibits that pathway, reducing CoQ10 synthesis. Mitochondrial CoQ10 depletion is linked to statin-associated muscle inflammation (Littarru & Langsjoen, 2007). For the insulin-resistant patient on statin therapy this creates a specific and legitimate reason to discuss CoQ10 with your physician. Modest independent evidence also supports modest reductions in fasting glucose and HbA1c with CoQ10 supplementation in T2DM populations (Moradi et al., 2018). Safety profile is favorable.

Myo-inositol functions as an insulin signaling second messenger. The strongest evidence is in PCOS and PCOS-spectrum presentations. It is a reasonable adjuvant for female insulin-resistant patients with hyperandrogenic features. Evidence outside this population is thinner.

Omega-3 fatty acids produce clinically meaningful triglyceride reduction at 2–4 grams of combined EPA/DHA daily, which is relevant because hypertriglyceridemia is common in insulin-resistant populations and carries independent cardiovascular risk. Food-first is preferable: fatty fish two to three times weekly. Supplementation is appropriate where dietary intake is consistently insufficient.

Magnesium is a cofactor for insulin receptor signaling, and deficiency is widespread in Western populations eating low whole-food diets. Replacement in deficient individuals is clinically indicated, with modest but consistent associations between magnesium status and insulin sensitivity (Barbagallo & Dominguez, 2015). Two points that must be stated clearly: first, confirm with your physician before starting over-the-counter supplementation, you may already be on replacement. Second, request serum magnesium measurement be included in your routine laboratory testing, it is inexpensive, widely available, and infrequently ordered without a specific request. Magnesium toxicity at excessive doses is real and should not be self-managed without monitoring.

Vitamin D deficiency is very common, and consistent associations between deficiency and insulin resistance are documented across multiple study designs (Pittas et al., 2007). Correcting documented deficiency is indicated but the same caveats as with magnesium: confirm existing replacement before supplementing, and request measurement during routine testing. Vitamin D toxicity carries serious medical risk including kidney stones, vascular calcification, and cardiac arrhythmia. Self-directed supplementation without documented deficiency and without monitoring is not advisable.

Popular Claims With Weak or Absent Evidence

Green tea and EGCG. The claim that green tea melts visceral fat is patently untrue. No meaningful clinical evidence supports significant visceral fat reduction or insulin resistance improvement at realistic intake levels. There is a genuine benefit available through substitution: replacing sweetened beverages, energy drinks, or high-calorie coffee preparations with unsweetened green tea removes a substantial daily glucose-fructose load.

Apple cider vinegar. Acetic acid produces a real, small, and vastly overstated reduction in postprandial glucose through gastric emptying delay. Claims in popular media exceed the evidence by an order of magnitude. Marginal value as a behavioral substitution.

Cinnamon. Small, inconsistent trials. Effect sizes do not reach clinical significance in better-designed studies. It adds great flavor, sprinkle it on when eating oatmeal, no significant benefit beyond that.

Thermogenic and metabolism-boosting supplements are among the worse class of dietary products requiring a clear a warning. The insulin-resistant population carries high background prevalence of hypertension, cardiac arrhythmia, and established cardiovascular disease. Many thermogenic supplements contain caffeine doses substantially exceeding a standard coffee serving, frequently combined with synephrine or yohimbine whose cardiovascular effects are additive. Hypertensive crisis, serious arrhythmia, atrial fibrillation, and acute cardiac events are well documented consequences of caffeine excess in cardiovascularly compromised patients (Palatini et al., 2009; Vlachopoulos et al., 2005). Read the label. If a supplement contains more caffeine than you would knowingly consume from coffee, do not take it without discussing it with your physician first. Better yet, don’t take it at all!

Detox and cleanse protocols have no mechanistic basis and no clinical evidence. Your liver and kidneys perform continuous detoxification without supplementation, provided they are functioning. This is not a category that warrants individual evaluation.

Pharmacological Intervention

Metformin remains the foundational pharmacological agent in insulin resistance and T2DM management, the most thoroughly validated, most affordable, and aligned with root pathophysiology. AMPK activation and suppression of hepatic glucose output are its primary mechanisms of action. Its long-term safety record is unmatched by any agent.

It is a treatment, not a cure: it manages the condition while taken and loses effect on discontinuation. For patients whose degree of insulin resistance warrants pharmacological support alongside lifestyle change, metformin is frequently appropriate and valuable along side lifestyle change.

GLP-1 receptor agonists represent the most significant pharmacological development in metabolic medicine in a generation. The cardiovascular, renal, and hepatic outcome data are real. The mechanism and the full clinical evidence base are covered in The GLP-1 Miracle Parts One and Two, which you can find in the archive. These are lifelong treatments, not cures. The STEP-4 withdrawal trial found that the majority of weight lost during GLP-1 agonist therapy is regained within one year of discontinuation, with metabolic parameters deteriorating correspondingly. The drug manages the condition does not resolve the root cause.

Pharmacotherapy and lifestyle changes are not competing options, they are complementary medical interventions. Medication as a bridge to the lifestyle change is a valid clinical strategy. Reduction or elimination of pharmacological dependence is achievable with sustained lifestyle changes.

Exercise Is an Insulin Sensitizer

Exercise is not primarily a caloric expenditure tool, is an insulin sensitizer one. Contracting skeletal muscle activates AMPK, which drives GLUT4 glucose transporter translocation to the cell surface through a pathway that is completely independent of insulin (Richter & Hargreaves, 2013). Muscle is taking up glucose directly, without requiring insulin to open the door. Simultaneously, exercise drives mitochondrial biogenesis, reduces muscle lipid accumulation, and promotes anti-inflammatory myokine secretion from contracting muscle.

Post-meal walking is the single most accessible metabolic intervention available. DiPietro et al. (2013) found that three 15-minute bouts of moderate post-meal walking reduced 24-hour glucose excursions more effectively than a single 30-minute morning walk in older adults at risk for impaired glucose tolerance. The mechanism is the AMPK-GLUT4 pathway described above, timed to intercept the postprandial glucose peak at its source. Accessible to any ambulatory person, implementable today. Ten minutes is a reasonable starting point; 15 minutes is what the evidence supports.

Incidental movement matters independently of structured exercise. Walking to nearby destinations, taking stairs, standing during phone calls accumulate meaningful metabolic benefit across the day. The independent metabolic risk of prolonged sitting is established and operates separately from how much formal exercise you do. It is not only how much you exercise but how much you move throughout the entire day.

Resistance training is the most important long-term metabolic investment available. Every kilogram of skeletal muscle preserved is glucose disposal capacity protected from the sarcopenia-insulin resistance feedback loop established in Part Two. Simple bodyweight resistance exercise at home performed consistently is enough for muscle preservation. Some examples include:

• Push-ups, pull-ups, chin-ups

• Dips, squats, lunges

• Step-ups

• Glute bridges, hip thrusts, single-leg deadlift, calf raises

Two to three sessions weekly of moderate resistance work, produces measurable long-term metabolic benefit.

Consistency is the requirement, not intensity. The insulin-sensitizing effect of exercise diminishes within 48–72 hours, requiring consistent renewal. A sustainable modest program produces better metabolic outcomes than an ambitious program abandoned after six weeks.

Sleep and Stress Are Not Secondary Recommendations

Seven to nine hours of sleep is a metabolic requirement. The Van Cauter laboratory’s research establishing sleep’s role in glucose regulation and insulin sensitivity (cited in Part Two) applies directly here in the treatment context. Improving sleep quality and duration is a critical metabolic intervention. Adding a supplement while sleeping only five hours a night is investing in the wrong intervention.

Chronic HPA axis activation is a direct metabolic driver, it is therefore a direct treatment target. Stress reduction is a metabolic intervention operating through cortisol and sympathetic nervous system pathways that drive insulin resistance.

The specific modality matters less than consistency: mindfulness, structured breathing, physical activity, social connection, professional psychological support where indicated. The goal is deliberate, consistent reduction of chronic HPA axis activation by whatever means you can actually sustain.

Education as Treatment

An educated person makes better choices because they understand what their choices are doing to their biology.

Biology is not your enemy, is a rational system responding to the environment it was given. Change the environment and the system will respond.

Remission is documented and can be achieved without bariatric surgery, expensive pharmacotherapy, or a complete life transformation.

A 15-minute walk after dinner, eggs instead of cereal, vegetables before the pasta, olive oil, seven hours of sleep. These changes are within reach of most reader of this piece.

I hope this series has served to expand your understanding about the main metabolic mechanism at the root of many of the worst modern diseases, and encourage you to implement the needed changes for a healthier you.

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

The surfaces food contacts during preparation and cooking interacts with heat, acidity, and time. Almost none of them are as alarming as the internet would have you believe, or as harmless as the cookware industry would prefer.

Non-Stick Pans

PTFE (polytetrafluoroethylene) is the non-stick polymer itself, the slick surface that makes eggs slide. PFOA (perfluorooctanoic acid) is a different chemical agent used in the manufacture of PTFE coatings, and the source of the documented population-level harm. PFOA was phased out of US manufacturing by 2013.

A large observational cohort of approximately 150,000 people in northern Italy exposed to polyfluoroalkyl substances (PFAS)-contaminated water between 1980 and 2018 showed elevated cardiovascular mortality and increased rates of kidney and testicular cancer. A nested case-control study in US Air Force men found a positive association between serum PFAS concentrations and testicular germ cell tumor risk (Dich et al., Environmental Health Perspectives, July 2023). A broader review links PFAS exposure to liver disease, thyroid dysfunction, impaired vaccine response, reduced fertility, and hypertension in pregnancy (Fenton SE et al., The Lancet Planetary Health, 2023, PMC10505820). PFOA has been classified as a possible human carcinogen by the International Agency for Research on Cancer.

PTFE begins releasing decomposition products above approximately 260°C (500°F). At extreme temperatures above 350°C, documented toxic fume release occurs, polymer fume fever in humans, and lethal toxicity in birds. A 2024 study examining aluminum cookware coated in PTFE-based and granite-style coatings found that prolonged heating above 250°C altered internal coating structures affecting release potential.

Direct product testing by the Ecology Center found that 79% of non-stick cookware contains PTFE coatings, and that “PFOA-free” labeling does not mean PFAS-free: PTFE is itself a member of the PFAS chemical family. Consumer Reports investigation (October 2022) found PFOA detectable in products claiming PFOA-free status due to manufacturing residues. The label that carries real meaning is PTFE-free.

Non-stick cookware is safe to use when you follow these three simple rules: never use at high heat, never use metal utensils, and replace when the coating shows visible damage.

Ceramic-Coated Cookware

The coating on ceramic-coated cookware is not fired clay or porcelain. It is primarily silicon dioxide, sand-derived, applied through a sol-gel manufacturing process and considered safe by toxicologists. These have no PFAS chemicals.

Consumer and laboratory testing has detected titanium dioxide (TiO2) and silicon dioxide (SiO2) nanoparticle migration from ceramic-coated cookware, particularly under abrasion conditions. High titanium levels were found in testing of GreenPan, Always Pan, and Caraway products (Bott J et al., Food Control, 2014, DOI: 10.1016/j.foodcont.2013.07.014). The EU has banned TiO2 as a food additive. The health implications of ingested nanoparticles from cookware remain under active investigation as of 2026.

The widely reported 1-3 year lifespan for ceramic-coated cookware reflects typical consumer handling. With correct handling (non-metal utensils, gentle cleaning, hand washing), ceramic-coated cookware can maintain its integrity for years. Visibly scratched or chipped coating is the signal to replace.

If you enjoy evidence-based medical information, subscribe to receive these articles delivered to your mailbox every week.

Subscribe now

The Plastic Problem

Cutting boards. Routine knife work on polypropylene and polyethylene cutting boards releases measurable quantities of microplastic particles into food. A controlled laboratory study by Hussain KA et al. (Environmental Science & Technology, 2023, 57(22):8225-8235) found that a single knife stroke releases an estimated 100-300 microplastic particles, with approximately 50% of released particles transferring to food rather than remaining on the board surface. Polypropylene boards released 5-60% more microplastic mass than polyethylene boards. Annual exposure from regular use is projected in the millions of particles. A systematic review in the Journal of the Academy of Nutrition and Dietetics (October 2025, DOI: 10.1016/S2212-2672(25)00435-6) confirmed these findings across peer-reviewed literature from 2016-2024.

Health implications of ingested microplastics remain under active investigation, but there is good case to be made for switching to safer wood or end-grain hardwood cutting boards.

Plastic containers and reheating. Heating food in plastic containers accelerates leaching of endocrine-disrupting compounds into food. Containers labeled BPA-free, particularly those containing BPS, carry The alternative is using glass or ceramic containers for reheating.

Styrene migration from heating food in Styrofoam containers is well documented. Styrofoam is never appropriate for reheating.

On Wooden Cutting Boards

Wooden boards require regular cleaning and periodic oiling to prevent cracking, bacterial harborage in deep cuts, and warping. End-grain hardwood is the gold standard, is knife-friendly, self-healing to a degree, and durable with proper care. Bamboo is harder than most wood, which makes it somewhat less forgiving on knife edges.

The Reliable Workhorses

Stainless steel is broadly safe, with one caveat. Nickel and chromium leaching into food from stainless steel cookware is real and documented. A controlled study by Kamerud KL et al. (Journal of Agricultural and Food Chemistry, 2013, 61(39):9495-9501, PMC4284091) found that after 6 hours of cooking tomato sauce in stainless steel, nickel concentrations increased up to 26-fold and chromium up to 7-fold versus baseline. Leaching is highest from new pans and stabilizes after approximately 6 cooking cycles; by the 10th cycle, 88 µg nickel and 86 µg chromium per serving were still detected.

These amounts remain below established harm thresholds for most people. For individuals with known nickel sensitivity or allergy, stainless steel is a dietary nickel source worth considering.

Cast iron and carbon steel both leach iron into food, and for most people this is either neutral or beneficial, particularly when cooking acidic foods. Well-seasoned cookware reduces leaching substantially. For people with hemochromatosis, cumulative iron loading from cookware is a problem and should be avoided.

Carbon steel pans behaves identically to cast iron, can be used interchangeably for any cast iron application while being significantly lighter and easier to handle. They carry the same caution regarding iron leeching, perhaps even more than cast iron.

Enameled cast iron is the cleanest all-purpose option in this category. The enamel layer eliminates direct iron leaching, is chemically inert, carries no coating chemistry concerns, and is durable enough to last a lifetime with reasonable care.

What About Silicone

Silicone is better than plastic but not as safe as stainless steel. Cyclic siloxanes (D4, D5, D6) are released from silicone bakeware during high-temperature use and have been associated with potential endocrine disruption, reproductive effects, and liver toxicity in some studies (Science of the Total Environment, 2023, 858:159697; PubMed PMID: 40876430, October 2025). Health Canada’s 2023 assessment concluded that siloxanes at current exposure levels are not harmful, and the regulatory consensus supports food-grade silicone within recommended temperature limits. Chemical migration decreases approximately 95% after the first few baking cycles, which means new items carry the highest off-gassing potential.

Aluminum and Renal Disease

Aluminum leaching from uncoated cookware into acidic foods is real and documented. For the general population the potential aluminum load is manageable, and anodized aluminum substantially reduces it. The Alzheimer’s association is a long-standing controversy that the current evidence does not support as a meaningful risk from cookware use. Both the Alzheimer’s Association and Alzheimer’s Research UK hold this position explicitly (Alzheimer’s Research UK position statement, updated August 2024).

The population-specific exception is patients with chronic kidney disease (CKD) and those on dialysis. StatPearls/NCBI Bookshelf (Aluminum Toxicity, NBK609094, updated October 2024) explicitly identifies aluminum cookware as a recognized exposure source and recommends avoidance in patients with impaired renal function. A case-control study of maintenance hemodialysis patients found a striking association: 100% of chronic aluminum toxicity cases had a history of aluminum utensil use, compared to 14.3% of controls, with a relative risk of 28.46 (95% CI: 1.81-445.3) (Gupta YK et al., National Medical Journal of India, 2019, PMID: 31309799).

Regarding Cooking Utensils

Metal utensils are appropriate for uncoated cookware only: stainless steel, cast iron, carbon steel, enameled cast iron. They are not appropriate for any coated cookware as they can damage the coating.

Silicone utensils and wooden utensils are excellent for all types of cookware.

An Informed Kitchen, Not a Perfect One

The goal here is to provide a working understanding of which materials carry conditional risks, which populations need to apply additional care, and which alternatives are supported by the evidence.

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

The harsh reality about how American healthcare works: how physicians and hospitals are paid determines how they behave. This is an observation that applies across every industry, institution, and professional class; medicine is not exempt from it.

The history of Medicare reimbursement policy since 1965 is one of the clearest available demonstrations of this principle. It is a forty-year sequence of payment reforms, each designed to correct the behavioral distortions of the previous model, each producing its own new set of distortions in turn.

Cost-Plus Reimbursement and the Incentive to Spend

Medicare back in 1965 reimbursed hospitals on a cost-plus basis: the hospital submitted its costs, Medicare paid those costs plus a margin. Every dollar spent returned a dollar plus profit. Prolonging services and expanding billing increased reimbursement. There was no financial penalty for inefficiency and no financial reward for restraint.

Many hospitals and physicians responded to this incentive as economic theory predicts: services were prolonged, billing was expanded. According to the Commonwealth Fund’s 2015 analysis of Medicare payment reform, annual Medicare spending per beneficiary rose from $472 in 1975 to $1,579 in 1985 a growth rate of 12.8% per year, or 5.3% adjusted for inflation.

The third-party payers and eventually Medicare raised legitimate concerns. The reform response was predictable.

The DRG and the Incentive to Discharge

The Social Security Amendments of 1983 established the Medicare Prospective Payment System based on Diagnosis-Related Groups (DRGs). Hospitals would receive a fixed payment per admission determined by the patient’s primary diagnosis, regardless of the actual costs incurred. Efficient hospitals retained the surplus, while hospitals whose costs exceeded the DRG payment absorbed the loss.

Average inpatient length of stay fell sharply following implementation, and Medicare Part A spending per beneficiary declined in the post-1983 period (Commonwealth Fund, 2015). The DRG had accomplished what it was designed for: it redirected the financial incentive from prolonging stays to shortening them.

The incentive to discharge efficiently and the incentive to discharge at the clinically appropriate moment are not the same. The prospective payment system was explicitly designed to give hospital administrators tools to influence individual physician discharge decisions (Fetter and Thompson, Yale University; cited in OIG HHS, OEI-09-00-00200).

Utilization Review Committees. These were hospital-based committees, required as a condition of Medicare participation, whose mandate was to review admissions and lengths of stay against established criteria. The committee reviewed physician decisions about admission and discharge against financial benchmarks and had authority to flag cases for further review or challenge clinical necessity determinations.

Physician-specific practice pattern data. The hospital’s internal data systems, fed by Medicare billing records, could generate reports showing each physician’s average length of stay by DRG compared to the hospital average and the national benchmark. That data was visible to administration and became the basis for what were called utilization management conversations, that in practice ranged from informal pressure to formal credentialing consequences in some institutions.

If you enjoy evidence-based medical information, subscribe to receive these articles delivered to your mailbox every week.

Subscribe now

RVUs, the AMA, and the Systematic Devaluation of Primary Care Medicine

The Resource-Based Relative Value Scale (RBRVS), authorized by Congress through the Omnibus Budget Reconciliation Act of 1989 and implemented in 1992, was designed to establish physician payment across specialties. The previous standard produced wide and largely arbitrary payment variability. The RBRVS replace it with a structured system in which each physician service was assigned a relative value unit (RVU) reflecting the time, skill, and resources required, and reimbursement would follow from that value.

Procedural intervention was systematically overvalued relative to primary care service. The reimbursement system does not reward what the most vulnerable patients need from their physician the most — time spent. It is a documented, persistent, and repeatedly criticized feature of the RVU schedule that the Medicare Payment Advisory Commission (MedPAC) and multiple independent analyses have identified and that the system has declined to correct (Laugesen, Fixing Medical Prices, Harvard University Press, 2016; PMC11977100).

The American Medical Association holds intellectual property rights to the Current Procedural Terminology (CPT) coding system. Every claim submitted to Medicare, Medicaid, and private insurance uses a CPT code. That code ownership generates royalty revenue for the AMA on the order of tens of millions of dollars annually (Laugesen, 2016).

The AMA’s Specialty Society Relative Value Scale Update Committee is a private physician committee, heavily weighted toward procedural specialists, whose recommendations to the Centers for Medicare and Medicaid Services (CMS) on RVU values are accepted in the large majority of cases. The RUC effectively determines how much each physician service is worth within the Medicare payment system, without the regulatory transparency requirements that apply to other government bodies.

The organization that owns the coding system controls the committee that determines the relative financial value of each code. This represents a conflict of interestthat has been allowed to persist for more than three decades.

The Assembly-Line Consequence: What RVU Undervaluation Looks Like in the Waiting Room

Primary care is the most cognitively intensive, least procedural domain in medicine. It is also, within the RVU framework, among the most financially disadvantaged relative to its overhead costs and clinical complexity demands.

The independent primary care physician facing overhead costs that consistently outpace per-encounter reimbursement has one available response within this system: increase encounter volume. More patients per day means less time per patient. Less time per patient means abbreviated encounters that cannot adequately address the increasingly complex medical care is expected to manage.

The system then compounds this by defining quality partly through metrics — preventive care completion rates, chronic disease control targets, medication adherence scores — that require exactly the time the reimbursement model makes financially unsustainable to provide. The physician is caught between what the metrics demand and what the economics permit.

The Mandate Response and the Hospital Readmissions Reduction Program

The Hospital Readmissions Reduction Program (HRRP), enacted as part of the Affordable Care Act in 2010 with financial penalties beginning in fiscal year 2013, is the most consequential case study in this pattern.

The stated goal was to reduce preventable hospital readmission; the financial driver: 3.3 million readmissions annually at an associated cost of $41.3 billion made reducing readmission a fiscal priority for CMS as much as a clinical one (Navathe et al., PMC6105419, 2018).

The HRRP created financial penalties for hospitals whose 30-day readmission rates for specified conditions exceeded risk-adjusted national benchmarks. By fiscal year 2017, 79% of acute care hospitals in the United States were subject to HRRP penalties, with up to 3% of a hospital’s entire inpatient Medicare reimbursement at risk (Navathe et al., PMC6105419). The program generated $528 million for CMS in fiscal year 2017 alone.

There is no financial reward within the HRRP for improvement. As national readmission rates decline over time, the benchmark moves with them, meaning hospitals face penalties even when they demonstrably reduce their own rates.

The Conflicting Mandate Trap: When Two Rational Policies Become One Irrational System

The DRG prospective payment system created a financial incentive to shorten hospital stays. The HRRP created a financial penalty for patients who return within 30 days of discharge. For the straightforward patient, an efficient discharge with adequate follow-up avoids unnecessary returns. For the typical Medicare beneficiary, with multiple interrelated chronic conditions, these conflicting goals are oftentimes irreconcilable.

The Unintended Consequences: What the Evidence Actually Shows

The penalty structure fell disproportionately on safety-net hospitals serving dual-eligible Medicare-Medicaid patients. Poverty and associated social health determinants independently increase readmission risk regardless of the quality of care provided. The HRRP risk-adjustment models did not adequately account for these factors, meaning these hospitals were effectively penalized for serving the patients most likely to be readmitted irrespective of care quality (Joynt and Jha, PMC4231573, 2014).

The mortality data is more troubling still. Four independent studies identified an association between HRRP implementation and increased 30-day mortality among heart failure patients, the program’s primary target population (Dharmarajan et al., PMC6589834, 2019; Gupta et al., JAMA Internal Medicine, 2021). The finding prompted Congress to mandate a formal review under the 21st Century Cures Act. The studies identified a temporal correlation between the program’s implementation and a mortality increase, did not prove the program caused the increase.

Penalty savings accrued to CMS while safety-net hospitals were financially weakened. This contradictory mandate system may have saved money in aggregate while concentrating the harm on the hospitals that serve the most vulnerable populations. Whether that constitutes a defensible policy outcome is a judgment I leave to the reader.

The Step-Down Facility Gap

Medicare patients discharged to skilled nursing facilities face a 25% likelihood of readmission or death within 30 days. In a review of 200 SNF discharges, 67% of readmissions were rated as potentially preventable, with patients reporting that inadequate facility care contributed to the majority of returns (Mack et al., PMC6069909, 2018). Across more than 1.5 million Medicare SNF discharges, facilities with the lowest staffing ratings had combined 30-day readmission or death rates of 25.5%, compared to 19.8% at the highest-staffed facilities (Kramer et al., PMC4203396, 2014).

The full examination of what skilled nursing facilities are, what they are not, and what patients and families need to understand before entering one belongs to the next piece in this series. What

The Honest Accounting

The cost pressures that drove each successive reform are real, documented, and threatening to the long-term fiscal sustainability of Medicare. The medical profession contributed to those pressures through the exploitation of cost-plus reimbursement that made reform both necessary and politically achievable. The architects of the DRG system, the RBRVS, and the HRRP were not indifferent to patient welfare, most were trying to improve it.

The policies examined here were designed for a population, but the unintended consequences are experienced by the individual.

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

Two papers published last week, both from Navdeep Chandel’s research group at Northwestern University, add a significant piece to that puzzle.

What We Already Knew

Metformin works through several distinct mechanisms simultaneously, which is part of why it is so effective.

Hepatic gluconeogenesis suppression. The liver continuously manufactures new glucose from non-sugar precursors, a process called gluconeogenesis. According to a 2023 review in Nature Reviews Endocrinology by Foretz, Guigas, and Viollet, suppression of hepatic glucose production has long been considered the drug’s primary mechanism of action.

AMPK activation. Metformin activates an enzyme called AMPK, which functions as a cellular fuel gauge: it shifts cells away from energy-consuming processes and toward energy conservation and glucose uptake. In simple terms: it makes cells more responsive to glucose already circulating in the bloodstream. As reviewed by LaMoia and Shulman in Endocrine Reviews (2021), AMPK activation contributes to metformin’s insulin-sensitizing effects across multiple tissues.

Gut microbiome modulation. Metformin alters the composition of the bacterial ecosystem in the gut in ways that appear beneficial for glucose metabolism. The mechanisms connecting microbiome changes to glycemic control are still being worked out, but the association is well established in human data (Foretz et al., 2023).

GLP-1 secretion. Metformin increases the release of GLP-1, a gut hormone that stimulates insulin secretion in response to meals and slows gastric emptying. This contributes to the drug’s lowering effect on after-meal blood glucose levels (Foretz et al., 2023).

A Pharmacokinetic Problem That Needed Solving

There was always something uncomfortable about the hepatocentric model, and researchers knew it.

Inhibiting complex I, the first and largest component of the mitochondrial electron transport chain and a key step in cellular energy production, requires metformin concentrations in the millimolar range when tested in isolated cell systems. That concentration is simply not what standard oral doses deliver to the liver or to the bloodstream.

Sebo et al. (2026), published in Nature Metabolism, measured tissue concentrations directly in the experimental animals used in their study and found what prior human pharmacokinetic literature had suggested: intestinal epithelial concentrations of metformin exceed plasma concentrations by up to 300-fold, and hepatic concentrations by 10 to 100-fold. The gut, specifically the lining of the small intestine, is where metformin concentrates most heavily after an oral dose, and where the drug reaches the concentrations required to inhibit complex I.

The New Evidence

To test whether complex I inhibition specifically in intestinal cells is necessary for metformin to work, the researchers created mice whose intestinal cells were genetically engineered to express a yeast enzyme called NDI1. This enzyme bypasses mammalian complex I entirely and is completely resistant to metformin’s inhibitory effect. In these mice, the drug can still circulate and reach other tissues, but the intestinal cells simply ignore its effect on their energy machinery.

The first paper, Reczek et al. (2026) in Science Advances, used mice with the NDI1 bypass expressed throughout the whole body. Metformin’s glucose-lowering effect was significantly attenuated compared to normal controls, under both standard and high-fat diet conditions. Tissue drug concentrations were equivalent in both groups, ruling out the possibility that the engineered mice were simply absorbing or distributing the drug differently.

The second paper, Sebo et al. (2026) in Nature Metabolism, used a more precise model: NDI1 expressed only in intestinal epithelial cells, using a targeting system called Villin-Cre. In these intestine-specific mice, metformin-induced glucose uptake by the intestine was abolished. Citrulline suppression was attenuated, as was GDF15 elevation, lactate production, and postprandial glucose lowering. Multiple independent readouts pointed in the same direction.

The mechanism works as follows. When metformin inhibits complex I in intestinal epithelial cells, those cells can no longer produce energy through their normal oxidative pathway efficiently. They compensate by shifting to an alternative strategy, metabolizing glucose through glycolysis instead. The gut, in effect, becomes a glucose sink: it intercepts a portion of the glucose arriving from a meal and use it before that glucose can reach the bloodstream in full. The intestine is doing metabolic work that was previously attributed primarily to the liver.

These are animal model findings. Mouse physiology is not human physiology, and the NDI1 bypass was incomplete, meaning the engineered mice still showed partial responses to the drug. This tells us that additional mechanisms are at work even in the mouse model. What proportion of metformin’s effect in humans operates through this intestinal mechanism will require dedicated human validation studies before we can answer with confidence.

The Citrulline Biomarker

Citrulline is an amino acid synthesized almost exclusively in the mitochondria of small intestinal cells. The enzymes that make it, CPS1 and OTC, depend on mitochondrial ATP. When complex I is inhibited and mitochondrial ATP output drops, citrulline synthesis falls. The circulating citrulline in your bloodstream is, in practical terms, a readout of what the mitochondria in your intestinal lining are doing.

Sebo et al. (2026) drew on two independent human datasets to test whether metformin produces the expected citrulline drop in people. The first, from Rotroff et al. published in Frontiers in Pharmacology (2016), involved 33 non-diabetic subjects. The second, from Aleidi et al. in Frontiers in Pharmacology (2021), involved 26 patients with obesity and type 2 diabetes. In both cohorts, citrulline was the most significantly downregulated metabolite following metformin treatment.

This human data does not prove that the intestinal mechanism drives glycemic control in people the way the mouse experiments demonstrate in animals. But it is consistent across two independent cohorts, and consistent with prior reports from other groups.

If you enjoy evidence-based medical information, subscribe to receive these articles delivered to your mailbox every week.

Subscribe now

What This Explains About Metformin in Practice

The gut mechanism, once you understand it, makes sense of several clinical observations that were previously explained incompletely or not at all.

Postprandial glucose control. Metformin is particularly effective at blunting the spike in blood glucose that follows a meal. Under the hepatocentric model, this was somewhat difficult to account for precisely. Under the gut-centric model, it is exactly what you would predict: the intestine is intercepting glucose at the point of absorption, buffering the postprandial load before it reaches the portal circulation.

Why mealtime dosing matters. Clinical guidance has long recommended taking metformin with food, primarily to reduce gastrointestinal side effects. The new data suggests a second, reason: the drug needs to be present in the intestinal lumen when glucose is arriving from a meal to function as a glucose buffer. Sebo et al. (2026) found that administering metformin continuously in drinking water, which produces chronic low-level exposure rather than mealtime boluses, failed to achieve glycemic control in the mouse model.

GI side effects. Nausea, bloating, and diarrhea are the most common reasons patients discontinue metformin, particularly early in treatment. Under the gut-centric model this is a direct consequence of where the primary action is occurring. The intestinal epithelium is adapting to a meaningful disruption in its energy metabolism. The clinical implication is that these side effects can be substantially minimized by increasing the dose slowly over weeks to months, allowing the gut time to adapt. This is consistent with what gradual titration reliably produces in practice.

GDF15 elevation. GDF15 is a stress hormone released by cells under metabolic pressure. Metformin raises GDF15 levels, and a 2020 paper in Nature by Coll et al. demonstrated that GDF15 mediates metformin’s effects on body weight and appetite suppression. The intestinal complex I inhibition model provides an explanation for why the gut would generate this signal: the cells are under energy stress, and GDF15 is part of their stress response.

There is evidence that metformin may blunt some of the mitochondrial adaptations to aerobic exercise in older adults, as reported in studies by Konopka et al. and Walton et al. in Aging Cell (2019). This does not change the risk-benefit for most patients with type 2 diabetes, but it is worth knowing, particularly for patients who are simultaneously pursuing resistance or aerobic training programs. The conversation belongs between patient and physician, with full awareness of the data.

Putting the Lactic Acidosis Risk in Perspective

If you have been on metformin for any length of time, you may have heard or read about lactic acidosis. It is the complication most frequently cited by people who are anxious about the drug.

Lactic acidosis is a serious condition in which lactic acid accumulates in the blood faster than the body can clear it. It carries significant mortality when it occurs. The anxiety around metformin and lactic acidosis, however, is mostly inherited from a different drug.

Phenformin was a biguanide, the same drug family as metformin, used for type 2 diabetes until 1977, when it was withdrawn from the US market because of an unacceptable rate of lactic acidosis: approximately 40 to 64 cases per 100,000 patient-years (Foretz et al., 2023).

Metformin-associated lactic acidosis in appropriately selected patients occurs at an estimated rate of 3 to 10 cases per 100,000 patient-years (Foretz et al., 2023), roughly one-tenth of the phenformin rate, and almost invariably in the context of significant confounders: severe renal failure, liver disease, hemodynamic instability, or situations where lactate clearance is already compromised for independent reasons.

The May 2026 papers provide an explanation for why these two drugs in the same chemical family carry such different risk profiles. The IC50 values, the concentration required to inhibit half of complex I activity, tell the story. Metformin’s IC50 is approximately 19,400 micromolar. Phenformin’s is approximately 430 micromolar (Bridges et al., Biochemical Journal, 2014; Turner et al., Diabetes, 2008, as cited in Sebo et al., 2026). Metformin requires roughly 45 times the concentration of phenformin to achieve the same degree of complex I inhibition.

In practice, metformin concentrates in the intestinal epithelium and produces its therapeutic effect there. It does not reach systemic complex I inhibition at standard therapeutic doses in patients with normal renal function. Phenformin, far more potent, produces systemic complex I inhibition more readily, leading to excess lactate production across multiple tissues.

In 40 years of practice, I encountered one single case of suspected metformin-associated lactic acidosis. The patient had significant renal failure, and in hemodynamic shock following acute blood loss from a traffic accident; two well known causes of metabolic acidosis. Attribution to metformin alone would have been a substantial inferential stretch here.

Metformin should be used with care or avoided in severe renal impairment, advanced liver disease, and acute illness with hemodynamic compromise. Within those boundaries, it has an outstanding safety record.

Berberine Mechanism Confirmed

Berberine is a plant-derived compound marketed as a “natural” alternative to metformin, and the “nature’s Ozempic” label has circulated widely in wellness spaces. These papers confirm that berberine does, in fact, work through the same intestinal complex I mechanism as metformin. In the intestine-specific NDI1 mouse model, berberine’s glucose-lowering effect was completely abolished, similar to metformin’s results.

The IC50 data is worth considering here. Berberine inhibits complex I at a concentration of approximately 15 micromolar. Phenformin, the drug withdrawn from the US market for causing fatal lactic acidosis at scale, requires approximately 430 micromolar. Metformin requires approximately 19,400 micromolar. Berberine is roughly 30 times more potent a complex I inhibitor than phenformin, and approximately 1,300 times more potent than metformin (Bridges et al., 2014; Turner et al., 2008, as cited in Sebo et al., 2026).

Berberine appears to be safe in practice, the reason is likely poor intestinal absorption. Berberine is poorly absorbed from the gut in standard supplement doses, and it is actively pumped back into the intestinal lumen by a transporter called P-glycoprotein. The drug is essentially trapped in the intestine limiting its systemic absorption.

Berberine is also a P-glycoprotein inhibitor: it can block the very pump that keeps it gut-restricted. Therefore is theoretically possible, that at higher doses berberine may progressively undermine its own containment mechanism leading to higher risk for lactic acidosis.

Sebo et al. (2026) tested this directly. Co-administering berberine with encequidar, an intestine-specific P-glycoprotein inhibitor, dramatically amplified berberine’s glucose-lowering effect in normal mice and had no effect in the intestine-specific NDI1 mice, confirming that the amplification worked by increasing intestinal complex I inhibition.

A number of commonly used medications inhibit the P-glycoprotein mechanism including grapefruit, verapamil, diltiazem, amiodarone, carvedilol, quinidine, dronedarone, clarithromycin (and other macrolide antibiotics), cyclosporine, ritonavir, itraconazole and ketoconazole. This interaction is unmonitored in supplement users, is not disclosed on berberine labels, and is entirely outside the safety oversight that applies to regulated pharmaceuticals.

There are no confirmed human case reports of berberine-induced lactic acidosis in the published literature. But the same mechanism that explains phenformin’s withdrawal from the market raises a coherent theoretical concern about berberine in patients on P-glycoprotein-inhibiting medications.

There is no rational clinical argument for choosing berberine over metformin in a patient who is a candidate for pharmacological treatment of type 2 diabetes or prediabetes. Metformin has decades of rigorous human trial data behind it, a known and manageable safety profile, regulatory oversight, quality-controlled manufacturing, and defined contraindications.

Berberine, being an unregulated over-the-counter supplement, has none of those things.

What This Means if You Are on Metformin

If you are currently taking metformin, nothing about the May 2026 findings changes your treatment. These papers add new scientific explanations of why it works.

The gut-centric model reinforces two practices that clinical guidance has long recommended and that are now understood to be important rather than merely convenient: take metformin with meals, and if you are starting the drug or increasing the dose, do so gradually. The intestine is where the action is, and it benefits from time to adapt.

If you have been avoiding metformin out of concern about lactic acidosis, the risk data and the information above are worth discussing with your physician in the context of your specific situation. Fear inherited from phenformin’s history, applied without adjustment to metformin’s actual pharmacology, has likely led patients to avoid a drug that would have served them well.

And if you have been taking berberine as an alternative to a conversation with your physician about metformin, this is a good moment to have that conversation.

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

So do the six that follow.

Cardiovascular Disease

Cardiovascular disease is the leading cause of death in the USA. Five mechanisms are at the center of this process:

• First, insulin resistance in the vascular endothelium impairs nitric oxide production through the PI3K-eNOS pathway. Nitric oxide is the primary vasodilatory and anti-atherogenic signal in the arterial wall. The endothelium becomes adhesive, permeable, and pro-inflammatory before any visible lesion exists.

• Second, the atherogenic dyslipidemic triad — elevated triglycerides, reduced HDL, small dense LDL predominance — facilitate accelerated plaque substrate. Small dense LDL particles are more susceptible to oxidation and are retained longer in the subendothelial space than large buoyant LDL. Standard lipid panels miss this pattern entirely.

• Third, the chronic systemic inflammation that both drives and is driven by insulin resistance promotes plaque instability. Vulnerable plaques rupture, stable ones do not.

• Fourth, elevated plasminogen activator inhibitor-1 (PAI-1) in insulin resistant populations impairs fibrinolysis, shifting the thrombotic balance toward clot formation (Alessi and Juhan-Vague, Arteriosclerosis, Thrombosis, and Vascular Biology, 2006). A plaque that ruptures in a patient with normal fibrinolytic capacity may produce a transient event. In a patient with PAI-1 elevation, the same rupture is more likely to produce vessel occlusion.

• Fifth, direct cardiac insulin resistance impairs myocardial glucose utilization and reduces ischemic resilience; the heart becomes metabolically inefficient before coronary disease produces ischemia (Riehle and Abel, Circulation Research, 2016).

These five mechanisms operate concurrently in the same arterial wall.

Metabolic disease is a powerful driver of cardiovascular disease through multiple mechanisms. While aggressive lifestyle interventions are needed to address the underlying insulin resistance, consult with your medical team BEFORE starting any exercise program to verify is safe for you.

Chronic Kidney Disease (CKD)

The kidney sustains damage through two parallel and independent pathways, and then amplifies the metabolic disruption that caused it.

The hemodynamic pathway operates through hypertension-driven glomerular hyperfiltration and the renin-angiotensin-aldosterone system (RAAS)-mediated glomerulosclerosis. Chronically elevated intraglomerular pressure damages the filtration architecture over years, producing the progressive proteinuria and glomerular filtration rate (GFR) decline that define CKD’s clinical course.

The metabolic pathway operates independently of blood pressure. Advanced glycation end-products accumulate in the glomerular basement membrane, impairing its structural integrity. Podocytes, the specialized cells that form the filtration barrier’s final layer, require intact insulin signaling to maintain their architecture. Podocyte insulin resistance impairs that architecture directly, producing proteinuria through a mechanism that antihypertensive therapy does not address (Welsh et al., Cell Metabolism, 2010).

Renal disease comes as a consequence of dual mechanisms: elevated arterial blood pressure causing direct damage to the filtration units, and insulin resistance impairing the glomerular filtration unit. While controlling arterial blood pressure is an important intervention, particularly with ACEI/ARB class drugs, lifestyle modification is essential to address the underlying metabolic disruption responsible for sustained renal damage.

If you enjoy evidence-based medical information, subscribe to receive these articles delivered to your mailbox every week.

Subscribe now

Non-Alcoholic Fatty Liver Disease (NAFLD)

NAFLD is the most anatomically direct consequence of hepatic insulin resistance on this list. The sequence from insulin resistance to hepatocellular carcinoma is defined at each step.

Visceral adipose tissue delivers free fatty acids into the portal circulation in volumes proportional to the adipose mass and insulin resistance severity. Hepatic insulin resistance simultaneously impairs the liver’s capacity to dispose of this lipid load through normal oxidative pathways. De novo lipogenesis adds to the substrate burden. VLDL secretion, insufficient to export the accumulating fat, leaves triglycerides depositing in hepatocytes leading to steatosis (fatty liver).

The transition from steatosis to non-alcoholic steatohepatitis (localized liver inflammation) is the critical inflection point. The same pro-inflammatory cytokine milieu driving peripheral insulin resistance — TNF-alpha, IL-6, and related mediators — activates Kupffer cells and hepatic stellate cells locally. Hepatic inflammation and progressive fibrosis (progressive scar tissue development) follow. Globally, NAFLD is estimated to affect approximately 25% of the world population, a prevalence that tracks the insulin resistance epidemic with precision (Younossi et al., Hepatology, 2016).

NAFLD progresses to cirrhosis through continued fibrotic remodeling, and cirrhosis carries a well-characterized risk of hepatocellular cancer, connecting NAFLD directly to the cancer section that follows.

Routinely described to patients as “a little fat on the liver”, steatosis is the initial finding eventually leading to localized liver tissue inflammation, cirrhosis and increased risk of liver cancer in the future. Fatty liver, although a benign finding, is a major red flag that should prompt adoption of aggressive lifestyle modification.

Obstructive Sleep Apnea (OSA)

Visceral obesity and the fat deposition that accompanies it reduce pharyngeal caliber and elevate the diaphragm, compromising functional residual respiratory capacity in the supine position. The airway that collapses during sleep is narrowed before the patient lies down.

Intermittent hypoxia activates the hypothalamic-pituitary-adrenal axis and sympathetic nervous system, generating cortisol and catecholamine surges that directly impair insulin signaling (Punjabi and Polotsky, Journal of Applied Physiology, 2005). Hypoxia-reoxygenation cycling produces oxidative stress that compounds the signaling impairment. Sleep fragmentation disrupts slow-wave sleep, the phase during which growth hormone secretion and nocturnal glucose regulation are concentrated.

Common diagnostic symptoms of OSA include:

• Excessive daytime sleepiness

• Loud, chronic snoring

• Interrupted breathing while asleep (apnea)

• Nocturnal gasping or choking

• Un-refreshing sleep (feeling tired after waking up)

• Frequent nocturnal awakenings

• Nocturia

• Morning headache

• Cognitive impairment / difficulty concentrating

• Irritability or mood disturbance

• Decreased libido

• Dry mouth or sore throat on waking

Insulin resistance mediated obesity is a mayor cause of OSA, and once OSA is present leads to endocrine dysfunction through stress induced cortisol elevation and oxidative stress that in turn worsens insulin resistance. If you have some of the symptoms listed above is time to seek urgent testing. Untreated OSA is associated with increase the risk of cardiac arrhythmias (particularly atrial fibrillation) and sudden cardiac death, among other complications.

Dementia

Insulin receptors are distributed throughout the central nervous system — densely expressed in the hippocampus, cortex, and hypothalamus — where they regulate synaptic plasticity, neuronal survival, and critical aspects of protein processing (Havrankova et al., Nature, 1978). Brain insulin signaling governs tau phosphorylation and amyloid precursor protein processing through pathways that, when impaired, generate the hallmark pathological features of Alzheimer’s disease (Craft and Watson, Lancet Neurology, 2004).

The “Type 3 diabetes” hypothesis proposes that Alzheimer’s disease represents, at least in part, insulin resistance localized to neural tissue. This framing is supported by postmortem brain insulin signaling data showing impaired IRS-1 and Akt activity in Alzheimer’s brains. It is not universally accepted as a formal diagnostic category, and prospective interventional causation in humans has not been established. The bridge to Alzheimer’s pathology runs through GSK-3 beta hyperactivation driven by Akt underactivity, producing tau hyperphosphorylation and impaired amyloid precursor protein processing (de la Monte and Wands, Journal of Diabetes Science and Technology, 2008).

In simple terms: the brain needs insulin to function properly. In Alzheimer’s some believe the brain loses its ability to respond to insulin. When insulin signaling breaks down in brain cells, it triggers a chain of events that leads to the toxic protein buildups — tangles and plaques — that are the hallmarks of Alzheimer’s disease. This connection is still being actively studied.

Vascular dementia represents a parallel pathway from the same metabolic root. The cerebrovascular consequences of insulin resistance — endothelial dysfunction, hypertension-driven small vessel disease, atherosclerotic large vessel disease — produce ischemic lesions that impair cognition through a mechanism entirely distinct from amyloid pathology. In clinical practice, mixed dementia combining both pathways is common.

The epidemiological picture is not subtle. Type 2 diabetes is associated with approximately doubled risk of Alzheimer’s disease in prospective cohort studies, and midlife metabolic risk factors predict late-life cognitive decline decades in advance (Biessels et al., Lancet Neurology, 2006).

Take away: The implication here is that metabolic health in your forties and fifties may lead to dementia in your senior years by several theoretical mechanisms, something to think about.

Cancer

The epidemiological associations between insulin resistance, obesity, and specific malignancies are robust. A systematic review and meta-analysis of prospective observational studies found elevated incidence of colorectal, breast, endometrial, pancreatic, hepatocellular, esophageal, and renal cell carcinomas in obese populations, with dose-dependent relationships in several cancer types (Renehan et al., Lancet, 2008). The hypotheses are compelling and experimentally supported in cellular and animal models. Prospective human interventional causation, the standard confirming insulin resistance as a modifiable cancer risk factor, is not yet fully established.

Four mechanisms lend support to the hypothesis:

• Chronic hyperinsulinemia activates insulin and IGF-1 receptors on susceptible cells, engaging the PI3K-Akt-mTOR proliferative cascade while simultaneously suppressing IGFBP-1 and IGFBP-3, the binding proteins that limit free IGF-1 bioavailability. The result is amplified mitogenic and anti-apoptotic signaling in tissues already exposed to a permissive growth environment (Pollak et al., Nature Reviews Cancer, 2004).

  In simple terms this favors tumor growth via unrestricted cell division and reduction in programmed cancer cell death.

• Insulin and IGF-1 stimulate vascular endothelial growth factor production in tumor-adjacent tissue, supporting the neovascularization that growing tumors require to sustain themselves beyond the diffusion limit of oxygen and nutrients (Warren et al., Journal of Biological Chemistry, 1996). A tumor that cannot recruit its own blood supply cannot grow beyond microscopic size.

• Chronic systemic inflammation, the shared metabolic environment of insulin resistance, impairs immune surveillance through mechanisms that are actively under investigation.

• Finally, the SHBG suppression produced by hyperinsulinemia elevates free estrogen bioavailability in hormone-sensitive tissues, a mechanism with direct relevance to breast and endometrial malignancy risk.

Observational data show metformin use in diabetic populations is associated with reduced cancer incidence (Evans et al., BMJ, 2005). This is a consistent finding across multiple studies.

For now these are observational findings fueling multiple hypothesis, prospective evidence is not yet available to confirm a concrete cause-effect relationship. This is one of the most actively evolving areas in metabolic medicine research today.

One Disruption. Twelve Conditions.

The human body is an inter-connected biological network, not a collection of independent systems. Disrupt one signaling system and the consequences propagate across multiple organ systems as evidenced here.

Part Five turns from the map to the intervention. What addressing insulin resistance at the root actually requires.

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

“Simpler to eat less carbs...”

If carbohydrates raise blood sugar, and damages your health, then eating fewer carbohydrates seems like the logical solution. That reasoning has been reinforced by a decade of social media consensus, bestselling diet books, and a wellness industry that has made carbohydrate fear into a reliable revenue stream.

Americans do over consume carbohydrates, and that contributes to metabolic disease. But the simplistic recommendation “eat less carbs”, although reasonable, fails to account for a more nuanced problem.

What Carbohydrates Actually Do

Your body runs on the two primary fuel sources: carbohydrates and fat.

Fat is energy-dense: breaking down fatty acids via beta-oxidation yields more total ATP per molecule than glucose, but it requires adequate oxygen delivery, functioning mitochondria, and time. Above approximately 60 to 70 percent of maximal aerobic capacity (VO₂max), fat oxidation cannot keep pace with energy demand.

Your muscles need something faster: carbohydrates.

Glycogen, the storage form of glucose packed into liver and skeletal muscle, exists specifically so the body can mobilize fast fuel on demand. It is a biological feature retained across hundreds of millions of years of evolution because rapid fuel mobilization is a survival requirement.

Understanding that carbohydrates are the body’s fast-access fuel reframes the question. The issue is not that carbohydrates exist in your diet, is how much you eat relative to how much you use.

The Activity-Matching Principle

At the peak of his competitive career, Michael Phelps trained five to six hours a day and reportedly consumed somewhere in the range of 8,000 to 12,000 calories, with carbohydrates constituting a substantial fraction of that intake. He was in superior metabolic condition to the vast majority of Americans eating a fraction of that. The reason: he consumed what his body required.

The Acceptable Macronutrient Distribution Range (AMDR) established by the Dietary Guidelines for Americans 2020-2025 and supported by the Institute of Medicine’s Macronutrient Report sets carbohydrate intake at 45 to 65 percent of total daily calories for adults, with a recommended dietary allowance floor of 130 grams per day, the minimum estimated to meet the brain’s glucose requirements without requiring hepatic gluconeogenesis as a primary supply mechanism. Sedentary adults should aim toward the lower end, moderately active adults sits in the middle and heavily active individuals towards the upper end without metabolic consequence, provided the sources are right.

The real problem most Americans have is not that they eat carbohydrates, is that they eat processed carbohydrate products.

If you enjoy evidence-based medical information, subscribe to receive these articles delivered to your mailbox every week.

Subscribe now

Not All Carbohydrates Are the Same

Even within natural, whole food carbohydrate sources, metabolic response varies. Glycemic index (GI) measures how quickly a carbohydrate-containing food raises blood glucose relative to pure glucose, on a scale of 0 to 100. Useful but incomplete.

Glycemic load (GL) corrects for the portion problem.

Watermelon has a glycemic index of approximately 72, high by standard classification. But a standard serving of watermelon contains relatively little carbohydrate by weight, so its glycemic load is around 4, which is low. Eating watermelon does not produce the same metabolic event as eating an equivalent glycemic-index-matched serving of white sandwich bread.

The Linus Pauling Institute Micronutrient Information Center at Oregon State University has compiled extensive GI and GL tables showing this pattern across dozens of foods that anti-carb messaging routinely condemns (i.e., bananas, pineapple, parsnips) whose glycemic loads at realistic portion sizes are moderate.

GL is the more clinically meaningful number when you are trying to evaluate the actual impact of a food; GI alone generates unnecessary fear. But even GL does not capture the full picture, because it does not account for what food scientists call the food matrix.

The Food Matrix And Industrial Processing

The food matrix is the physical cellular architecture of whole food. That structure governs how quickly carbohydrates are absorbed, independently of their chemical composition.

A whole banana delivers glucose within an intact cellular matrix. The carbohydrates are physically encased in plant cells that must be mechanically disrupted by chewing and then enzymatically broken down by digestion before absorption begins.

The result: glucose enters the bloodstream gradually.

Commercial banana pudding made with modified corn starch, sucrose or high-fructose corn syrup, refined wafers, emulsifiers, and artificial banana flavoring has no meaningful matrix. The industrial manufacturing process has destroyed whatever structure existed in the source ingredients and replaced it with rapidly-absorbed refined starches and free sugars. The glucose arrives faster, the insulin demand is higher, and the satiety signal is weaker: the food matrix was profoundly altered before it reaches your mouth.

A systematic review by Dahl et al. published in Frontiers in Nutrition (2021, DOI: 10.3389/fnut.2021.673364) found that intact starch structure significantly reduces postprandial glucose and insulin response compared to processed forms with identical macronutrient content. Earlier foundational work by Haber et al. published in the Lancet (1977) demonstrated that equal carbohydrate loads from intact apple, pureed apple, and apple juice produced different insulin responses. Juice and puree apple increased insulin demand despite producing similar glucose curves suggesting that matrix disruption elevates insulin response even when the glucose profile looks comparable. A 2025 overview in Critical Reviews in Food Science and Nutrition (Forde et al., DOI: 10.1080/10408398.2025.2453074) synthesized the current state of food matrix science and confirmed that physical food structure is an independent determinant of metabolic response.

Sourdough bread made through long fermentation produces meaningfully lower glycemic response than the same flour baked into conventionally produced commercial bread. The fermentation process partially pre-digests the starch, modifies the gluten matrix, and lowers the pH, all of which slow glucose absorption.

Same flour, different process, different metabolic results.

Legume-based pasta made from lentil, chickpea, or black bean flour, provides carbohydrate alongside fiber and protein in a matrix structure that further attenuates postprandial glucose response, making it a practical and under appreciated option for readers managing blood sugar.

So How About Ketogenic Diets

The ketogenic diet is the ultimate expression of the low carb philosophy.

In type 2 diabetes management, short-term ketogenic interventions have produced clinically meaningful reductions in HbA1c and triglycerides and achieved diabetes remission in some patients. In refractory epilepsy, ketogenic diet is an established therapeutic tool with decades of clinical use.

The honest limitation is that most ketogenic diet research is short-term. Patikorn et al. published an umbrella review of meta-analyses of randomized clinical trials (RTC) in BMC Medicine (2023, DOI: 10.1186/s12916-023-02874-y) covering 68 RCTs. The median trial follow-up was 13 weeks. Of 115 associations examined, only four were supported by high-quality evidence: reduced triglycerides in two analyses and reduced seizure frequency. Thirteen weeks is not long enough to evaluate a dietary pattern most of its proponents recommend for life.

Meta-analyses of ketogenic diet RCTs consistently show favorable effects on triglycerides and HDL, but also a mean LDL-C increase of approximately 8.5 mg/dL (Mozafari et al., ScienceDirect 2026, DOI: 10.1016/j.jacl.2026.00261; American Journal of Clinical Nutrition meta-analysis, 2024, DOI: 10.1016/j.ajcnut.2024.00445). Early blood pressure reductions seen at six months were not sustained at twelve months and beyond. At least one analysis suggested the LDL increase may reflect larger, less atherogenic particle fractions but that question remains unresolved.

The evidence-based clinical position on ketogenic diets is this: validated short-term therapeutic tool for specific populations, unanswered question as a long-term dietary pattern for general use.

The Real War

Here is what the evidence consistently points toward: ultra-processed food, not carbohydrates, is the primary dietary driver of the metabolic disease epidemic.

The most compelling evidence comes from a randomized controlled trial by Hall et al. published in Cell Metabolism (2019, DOI: 10.1016/j.cmet.2019.05.008). He recruited 20 adults and admitted them to an inpatient metabolic research ward for four weeks. Participants were randomly assigned to either an ultra-processed diet or an unprocessed diet for two weeks, then crossed over to the other condition. Both diets were matched for presented calories, macronutrients, sugar, sodium, and fiber. Participants were offered as much food as they wanted and told to eat as much or as little as they liked.

On the ultra-processed diet, participants consumed an average of 508 additional calories per day, weight gain followed. On the unprocessed diet, they spontaneously ate less and lost weight. The macronutrient composition on paper was identical, the difference was the food matrix.

This is causal evidence is limited by a sample of 20 participants in a controlled inpatient setting, and a short 28-day duration. But the direction of causality is established: ultra-processed food drives overconsumption through mechanisms that operate independently of macronutrient content.

Those mechanisms are not fully characterized. Current hypotheses include disrupted satiety signaling, altered oral processing (ultra-processed food requires less chewing, which affects cephalic phase insulin and satiety hormones), direct effects of food additives on gut microbiome and appetite regulation, and hyperpalatable combinations of fat, sugar, and salt engineered to override normal satiation. None of these mechanisms have carbohydrates as the primary variable.

The food industry has benefited from a public discourse fixated on macronutrients. Macronutrient anxiety is commercially useful: it sells low-carb products, ketogenic supplements, protein bars, and meal replacement systems.

It also redirects attention away from the manufacturing process: the destruction of the food matrix, the addition of refined starches and free sugars, the replacement of real ingredients with engineered substitutes.

That is the actual problem.

The myopic public focus about carbohydrate grams protects industrial food from scrutiny.

Where This Leaves You

You need to recognize the difference between a food with an intact matrix and a product whose matrix has been industrially destroyed. An apple or a banana are not metabolic threats after all. Match your carbohydrate intake to your activity level, choose whole food sources with intact matrices, reduce ultra-processed food.

The real problem is the processing, not the macronutrients.

The war on carbohydrates was never the right war. It was a war fought on the wrong battlefield, against the wrong enemy, while the actual problem continued largely undisturbed. The reader who wrote “simpler to eat less carbs” was not wrong. But simpler is only useful if it aims at the right target.

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

A $69 Billion Market

The US dietary supplement market reached $69 billion in 2024 and is growing at approximately 7–8% annually, with projections toward $130 billion by 2033 (Nutrition Business Journal, via Nutraceuticals World, April 2025). The broader US wellness economy is valued at $2 trillion (Global Wellness Institute, March 2025).

The Federal Trade Commission has primary jurisdiction over supplement advertising claims. Over the past decade, the FTC brought approximately 120 enforcement actions challenging health claims for dietary supplements while explicitly acknowledging it lacks the staffing to police a $70 billion industry (FTC Health Claims page; FTC Health Products Compliance Guidance, 2022). Enforcement activity has measurably declined since 2025 under the current administration (KFF Health News, August 2025).

A lawsuit currently pending (Xlear v. FTC, filed 2025) seeks to shift the burden of proof for supplement health claims, moving the obligation from manufacturers proving their claims, to the government proving claims are false instead (KFF Health News, August 2025; PolitiFact, August 2025). If successful, the framework that produced what you are about to read about Prevagen would be substantially dismantled.

The Four Levels of Evidence

Level 1: Cell Studies

A cell study exposes isolated human or animal cells in a laboratory dish to a compound and observes what happens. These studies establish whether a biological interaction is chemically possible under controlled laboratory conditions. They cannot establish whether that interaction occurs in a living human body at concentrations a product can actually deliver.

When a product claims it “supports cellular repair” and cites cell study data, you are reading a Level 1 finding dressed as a clinical outcome.

Level 2: Animal Studies

Animal studies establish biological plausibility in intact living organisms. They move beyond the dish into a living system, but cannot establish human efficacy. The majority of compounds showing promise in animal models fail in human trials, a pattern documented across decades of drug development (Hay M et al., Nature Biotechnology, 2014).

Thalidomide a striking illustration: effective and well-tolerated in animal models, catastrophic in humans when used during pregnancy, causing severe limb malformations in thousands of children.

When a product’s scientific bases is limited to animal research, human efficacy remains unestablished by definition.

Level 3: Observational Human Studies

Observational studies generate findings in actual human beings, but they cannot establish causation.

The main limitation is confounding: hidden factors alongside the thing being studied that can make it look responsible for an outcome it didn’t actually cause.

In supplement and wellness research three confounders are common:

• Healthy user bias: supplement users differ from non-users in exercise habits, diet quality, smoking rates, and health literacy.

• Socioeconomic confounding: wellness products are usually purchased by higher-income populations with better baseline health outcomes for reasons unrelated to supplementation.

• Recall bias: self-reported supplement use is unreliable.

No statistical adjustment fully eliminates confounding from observational data.

Level 4: Double Blind Placebo Controlled Randomized Trial

A double-blind placebo-controlled randomized trial (DB-RCT) randomly assigns participants to either an active intervention (the study subject) or an indistinguishable inert comparator (placebo), while keeping both participants and investigators unaware of group allocation until data collection is complete. Randomization distributes known and unknown confounders between groups; blinding eliminates expectation and assessment bias on both sides.

Together these features make the DB-RCT the only study design capable of establishing causation rather than association which is why it sits at the top of the evidence hierarchy. While is the best research design available, is not free of occasional design problems.

If you enjoy evidence-based medical information, subscribe to receive these articles delivered to your mailbox every week.

Subscribe now

Open-Label Studies and Testimonials

Open-label studies are conducted without blinding: participants know what they are receiving, and investigators know what they are administering. Testimonials are self-reports from people who used a product and noticed something. Both are the most frequently cited evidence in wellness marketing and carry the least scientific weight.

Three biases operate in the absence of blinding:

• Prescriber bias: an investigator who believes in the intervention unconsciously interprets ambiguous findings favorably.

• User bias: a participant who knows they received an active treatment attributes any positive findings to the treatment itself.

• And the placebo effect: when a person believes they are receiving something beneficial, reported physiological and subjective changes can occur independent of any actual pharmacological activity. Without a control to compare, is not possible to reliably determine cause and effect.

The placebo effect is real, reproducible, and well-documented across clinical trial literature (Hróbjartsson A, Gøtzsche PC, New England Journal of Medicine, 2001). The effect is particularly large for subjective outcomes: energy, mood, pain, and wellbeing. This are precisely the outcomes wellness products most commonly claim to improve.

Where the Marketing Lives

Each level of evidence is legitimate for what it shows. The problem is the claim made from it. Backed by science, clinically proven or any other such phrases may not mean what you think they do.

Two additional problems compound the design issue:

• The dose gap: a compound effective at laboratory concentrations may be pharmacologically inactive at the concentration delivered by a consumer product.

• The population gap: a finding in patients with a diagnosed deficiency, a specific age group, or a particular clinical condition does not automatically generalize to a healthy adult purchasing a supplement.

The Prevagen Case

Quincy Bioscience, the manufacturer, conducted an actual clinical trial, the Madison Memory Study. The trial showed no statistically significant improvement over placebo in its primary analysis. The company then conducted 30 post-hoc subgroup analyses, identified three results that favored the product, and built a “clinically shown to improve memory” marketing claim on that foundation.

Post-hoc subgroup analysis, running statistical tests on subsets of data after the primary analysis has failed, is a well-recognized form of data mining that produces findings by chance rather than by design.

The FTC and the New York Attorney General filed suit in 2017. After seven years of litigation and more than $165 million in sales, a federal court issued an injunction in December 2024 ordering removal of all memory-improvement claims (FTC press release, December 10, 2024; NY Attorney General press release, May 2024).

Three Questions Worth Asking

The entire framework collapses into three questions you can apply in under sixty seconds to any health claim from any source.

What kind of study is this? Cell study, animal study, observational data, open-label report, or randomized controlled trial. The answer tells you immediately what the evidence can and cannot establish.

Does the claim match what the study actually measured? A finding in isolated cells does not support a claim about human outcomes and showing an association does not support a claim of causation. The question is whether the study supports the claim being made.

At what dose, and in what population? A compound studied at 10 grams per day in elderly patients with confirmed cognitive impairment tells you absolutely nothing about a 500-milligram daily capsule marketed to healthy adults in their forties.

What Can We Do

Cell studies and animal research are essential early steps in understanding how biology works. Observational data has driven some of the most important public health advances of the past century. The problem is the claim made from it; the gap between what a specific piece of evidence was designed to establish and what a manufacturer asserts it proves.

The main question is: does the level of evidence cited as proof, supports the claim made?

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

As physicians we prescribe a medication with the understanding that decision reflects the accumulated weight of scientific evidence. But what happens when science itself becomes the business. Who are we left to trust then?

Who Funds the Evidence

The entity with the greatest financial interest in the outcome of clinical research is also its primary funder.

Let that fact sink in for a moment.

Between 2006 and 2014, the number of NIH-funded clinical trials registered at ClinicalTrials.gov fell 24 percent, from 1,376 to 1,048, while industry-funded trials grew 43 percent, from 4,585 to 6,550 (Ehrhardt et al., JAMA, 2015). The NIH budget fell 14 percent in real terms over the same period, which explains part of the decline.

How Outcomes Get Shaped Without Falsifying Data

Industry-funded trials produce more favorable outcomes for sponsored products than independently funded research. It has been replicated across multiple independent reviews over two decades and published in the highest-tier medical literature (Bekelman et al., JAMA, 2003; Lexchin et al., BMJ, 2003; Lundh et al., Cochrane Database of Systematic Reviews, 2017).

Trial design can be manipulated to favor a sponsor’s product before a single patient is enrolled:

• Selecting patient populations where the drug performs best, choosing dosing regimens that favor the treatment arm, selecting a comparator at sub-therapeutic dose so the experimental drug appears superior.

• Composite endpoints combine a hard outcome like death with softer outcomes like hospitalization, inflating the apparent magnitude of benefit.

• Selective publication ensures that positive trials appear in the literature promptly while negative trials are delayed or never published, producing a body of evidence that systematically overstates benefit.

• Truncated follow-up ends a trial before long-term harms have time to accumulate.

• Subgroup mining searches through disaggregated data until a favorable result surfaces, then publishes that result as if it were the primary finding.

Technical accuracy and intellectual honesty are not the same thing, and a system engineered to produce misleading conclusions from accurate data is a dishonest system.

How Truthful Numbers Lie

The ASCOT-LLA trial, published in The Lancet in 2003, found that atorvastatin reduced the risk of heart attack by 36 percent in the studied population (Sever et al., Lancet, 2003). That figure, the relative risk reduction, was mathematically accurate and appeared in direct-to-consumer advertising.

What the advertising did not communicate was the absolute risk reduction: the heart attack rate fell from approximately 3.0 percent in the placebo group to 1.9 percent in the treatment group over the study period. The 36 percent relative risk reduction is simply the mathematical expression of that 1.1 percentage point absolute difference as a proportion of the 3.0 percent baseline risk.

Both numbers describe the same finding. They produce entirely different impressions of benefit in the mind of a patient or a physician who is not trained to recognize which one is being presented.

Atorvastatin has demonstrated genuine clinical benefit in appropriate patient populations, and nothing in this example should be taken as stating otherwise. This practice is not unique to this drug or this campaign. It was and remains a pervasive feature of pharmaceutical marketing and of how trial results are framed in publications and communicated to the clinical community.

If you enjoy evidence-based medical information, subscribe to receive these articles delivered to your mailbox every week.

Subscribe now

Statistically Significant, But Clinically Significant?

It appears in pharmaceutical marketing, journal abstracts, prescribing guidelines, and conversations between physicians and patients. It carries the authority of clinical judgment implying that someone with medical training has evaluated and determined it matters.

A trial with enough participants can demonstrate statistical significance for an effect so small it changes nothing about how a patient feels or functions. The logical question becomes, is the effect clinically meaningful?: significant enough to matter in terms of how a patient feels, functions, survives, or dies. The final question is, do the benefit has clinical value?: whether the demonstrated effect is worth the cost or the risk, versus available alternatives.

The influenza antiviral oseltamivir (Tamiflu) is the clearest documented illustration of the gap between these three questions. The drug received FDA approval in 1999, promoted as reducing the severity and duration of influenza and preventing serious complications. Governments worldwide stockpiled it at a cost of billions of dollars during pandemic preparedness planning. The supporting evidence was largely manufacturer-funded, and the full underlying trial data was withheld from independent researchers for years.

When the Cochrane Collaboration obtained and analyzed the complete clinical study reports, the findings were precise (Jefferson et al., Cochrane Database of Systematic Reviews, 2014). Tamiflu reduced time to first alleviation of symptoms in otherwise healthy adults by 16.8 hours, from approximately seven days to 6.3 days. The independent also review found no good evidence to support reduction in hospitalizations, serious complications, or transmission.

Statistically significant, yes. Clinically meaningful or valuable, not in my opinion.

The Ghost-Writing Scandal

Merck created a systematic editorial process for its arthritis drug rofecoxib (Vioxx) in which company employees and contracted medical publishing companies wrote the manuscripts, determined the target journals, and arranged for the names of external academic investigators to appear as primary authors after the content was completed. Investigators received honoraria for lending their names to research they did not conduct and papers they did not write (Ross et al., JAMA, 2008).

This was documented through internal company materials released during litigation and subsequently published in JAMA. The drug was voluntarily withdrawn from the market in September 2004 after research demonstrated it doubled the risk of heart attack and stroke if taken for more than 18 months. It had been on the market for five years. Merck subsequently settled with plaintiffs for $4.85 billion.

On reviewing the JAMA documentation, the journal’s editor-in-chief, Catherine D. DeAngelis, stated: “The manipulation is disgusting. I just didn’t realize the extent.”. The Vioxx case don’t represent an isolated failure by a single company acting in an unusual way. The JAMA editorial accompanying the Ross findings noted explicitly that these practices were not uncommon, calling for immediate reform.

The FDA’s Structural Vulnerability

The FDA’s approval process requires the manufacturer to submit the clinical trial data supporting safety and efficacy. The agency evaluates that data but does not independently conduct or replicate the trials. The integrity of the process therefore depends entirely on the integrity of data submitted by the entity with the most direct financial interest in the approval.

Since its establishment in 1992, the accelerated approval pathway has allowed drugs onto the market based on surrogate endpoints, indirect biological measures assumed to predict clinical benefit, before actual clinical benefit has been demonstrated. Post-approval confirmatory trials are required to verify that benefit but in practice, nearly half (112 of 253) of the drugs authorized through this pathway had not been confirmed as clinically effective as of a 2021 BMJ investigation and only 16 had ever been withdrawn (Mahase, BMJ, 2021). Twenty-four of those unconfirmed drugs had been on the market for more than five years, some for more than two decades.

The Institute for Clinical and Economic Review reported in April 2021 that FDA’s reluctance to follow through on withdrawal when confirmatory trials were not completed meant that sponsors had little practical incentive to conduct them. Aduhelm — an Alzheimer’s drug approved at $56,000 per year despite internal FDA scientific objections, subsequently discontinued after confirmatory trials failed — is the most publicly visible recent illustration of what that failure costs. More than 30 oncology drug indications have been withdrawn in the past five years as the FDA recalibrates its standards.

Guideline Committees and Threshold Creep

Clinical practice guidelines are the mechanism by which research findings become prescribing behavior at scale. They tell physicians what to treat, when to begin, and with what. The committees that write them have historically included members with significant financial relationships with the pharmaceutical industry (Bekelman et al., JAMA, 2003; Angell, The Truth About the Drug Companies, 2004).

The documented pattern across cardiovascular medicine, lipid management, and diabetes care is consistent: treatment thresholds have been progressively lowered over time, more patients defined as requiring pharmacological intervention, and combination therapy established as standard of care with earlier initiation. Abramson and Wright documented concerns about this directional pattern specifically in lipid-lowering guidelines as far back as 2007, noting that the guidelines had moved ahead of the evidence base supporting them (Lancet, 2007).

What This Produces at the Bedside

The clinical endpoint of these intersecting forces is visible in the care of older patients across American medicine. Polypharmacy defined as five or more concurrent medications, is common and consequences well documented: increased adverse drug events, drug-drug interactions, falls, cognitive impairment, and hospitalizations (Masnoon et al., BMC Geriatrics, 2017; Hajjar et al., American Journal of Geriatric Pharmacotherapy, 2007).

I observed this repeatedly: elderly patients presenting with altered mentation, cognitive changes, confusion, behavioral disturbance, that on careful medication review proved to be the consequence of multiple centrally acting and psychoactive drugs prescribed by different providers, each subsequent prescription treating a symptom that was likely a side effect of from a prior one.

To add insult to injury, these patients stayed in the hospital, underwent a battery of additional tests despite the obvious cause, adding tens of thousand of dollars in unnecessary healthcare expenses.

A Reasonable Proposal and an Honest Assessment of Its Prospects

One simple structural reform could address this conflict: pharmaceutical companies seeking FDA approval should be required to contribute to a pooled, independently administered research fund from which grants are awarded to unaffiliated investigators who design and conduct the confirmatory trials the FDA requires. The company that developed the drug no longer has any control over the trial that evaluates it.

The reason of why it does not exist: the financial interests that would fund this arrangement are the same interests that fund the political process required to mandate it.

In Science We Still Trust… But…

My point here is not that medications in common use are not working or are unsafe. The point is we should all demand more transparency about conflict of interest in medical research and support independent research at a governmental level.

When a new prescription is proposed, three questions are worth asking:

• What is the absolute risk reduction this drug provides for someone with my specific profile, not just the relative risk reduction?

• What are the alternatives, including non-pharmacological ones?

• If I am already taking multiple medications, who is reviewing the complete list for interactions?

These are not adversarial questions. They are the questions a well-informed patient asks. Your physician will recognize them as exactly that.

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

We will start with the quintessential metabolic condition: Type 2 Diabetes Mellitus.

Type 2 Diabetes Mellitus

Diagnosis of Type 2 Diabetes Mellitus (T2DM) marks the moment when the body can no longer keep up with progressive insulin resistance. Glucose levels finally rise above normal. However, insulin resistance is an evolving process present but undetected for years, we call it pre-diabetes.

Accepted diagnostic criteria for diabetes as of the date of this article are:

• Fasting Plasma Glucose (FPG) ≥126 mg/dL (7.0 mmol/L) after ≥8 hours of fasting

• 2-Hour Plasma Glucose (2hPG) during 75g OGTT ≥200 mg/dL (11.1 mmol/L)

• HbA1c ≥6.5% (48 mmol/mol)

• Random Plasma Glucose ≥200 mg/dL

The classic presenting symptoms include:

• Polyuria — excessive urination

• Polydipsia — excessive thirst

• Polyphagia — excessive appetite

• Unexplained weight loss

As of 2021, 537 million adults worldwide were living with diabetes, a figure projected to reach 783 million by 2045 (IDF Diabetes Atlas, 10th Edition, 2021). In the United States alone, approximately 96 million adults, about one in three, have pre-diabetes, and the majority are unaware of it (CDC National Diabetes Statistics Report, 2022).

Common complication of diabetes include: retinal damage leading to loss of vision, cardiovascular disease, stroke, erectile dysfunction, sensory and autonomic nerve damage, and several others. One complication deserving special attention: T2DM is the most common cause of non-traumatic lower extremity amputation in the USA.

Is important to realize that the inflammatory vascular damage responsible for most diabetic complications starts 5-10 years before a formal diagnosis, and progresses undetected during the pre-diabetic phase. Early diagnosis and aggressive lifestyle modification can stop and reverse disease progression.

Diabetes mellitus will be covered in detail on a separate series. The initial article is already published here.

Hyperlipidemia

When the liver becomes insulin resistant, it continues to overproduce very low-density lipoprotein (VLDL) particles while simultaneously impairing triglyceride clearance. Cholesteryl ester transfer protein activity depletes high-density lipoprotein (HDL) in exchange for triglycerides, and hepatic lipase remodels the remaining low-density lipoprotein (LDL) particles into the small, dense subtype that penetrates the arterial wall more readily and persists longer in circulation.

The result is the atherogenic dyslipidemic triad: elevated triglycerides, reduced HDL, and small dense LDL predominance, a pattern linked to hepatic insulin resistance and substantially more atherogenic than elevated LDL cholesterol alone (Taskinen and Borén, Atherosclerosis, 2015).

While standard lipid panels report total LDL cholesterol, they do not distinguish large buoyant LDL from small dense LDL. A patient with insulin resistance can return a total LDL within the normal range with a large portion of those being very dense LDL particles.

A future article will address the assessment and management of insulin resistance-driven dyslipidemia in full.

If you enjoy evidence-based medical information, subscribe to receive these articles delivered to your mailbox every week.

Subscribe now

Obesity and Metabolic Syndrome

Excess adiposity, particularly visceral fat, releases free fatty acids and pro-inflammatory cytokines that directly impair insulin signaling at the receptor and post-receptor level. As insulin resistance deepens, compensatory hyperinsulinemia takes over and chronic hyperinsulinemia promotes fat synthesis and inhibits fat mobilization simultaneously.

Hyperinsulinemia also drives central leptin resistance, impairing the hypothalamic satiety signal that would otherwise prevent excess caloric intake. The result is a system that is simultaneously storing more fat, burning less of it, and receiving a progressively degraded satiety signal.

Metabolic syndrome is the clinical name for the point at which this process becomes visible, is defined by the presence of these five findings: abdominal obesity, elevated fasting triglycerides, reduced HDL cholesterol, elevated blood pressure, and impaired fasting glucose.

Obesity is more responsive to lifestyle modification at the early stages, when increasing subcutaneous fat is first detected. As abdominal (visceral) fat begins accumulating, the self sustaining mechanisms makes loosing weight more difficult the longer you wait to make changes.

Obesity is extensively discussed in two articles elsewhere on this site: Part One and Part Two.

Polycystic Ovary Syndrome

Insulin resistance is present in the majority of women with PCOS regardless of body weight (Teede et al., 2018). Lean women with PCOS carry the same underlying metabolic driver. The hyperinsulinemia-CYP17A1-ovarian androgen axis operates independently of obesity which is why the condition’s metabolic trajectory parallels insulin resistance severity.

Women with PCOS carry substantially elevated lifetime risk of type 2 diabetes, cardiovascular disease, and non-alcoholic fatty liver disease, because all of them share the same metabolic root. The main management for this condition is the diabetes drug metformin, it addresses some of the pathways leading to insulin resistance.

If you are pre-menopausal woman with abdominal fat accumulation you need to take this seriously. Start aggressive lifestyle modification and seek additional testing from your doctor: specifically sex hormone-binding globulin (SHBG) levels.

Hypertension

Arterial hypertension is usually not associated by most people as related to insulin resistance. While there are other causes of hypertension, if you have abdominal obesity, abnormal lipids and/or pre-diabetes, your hypertension is likely the result of underlying insulin resistance.

Different mechanisms lead to insulin resistance mediated arterial hypertension.

• First, chronic hyperinsulinemia directly stimulates sympathetic nervous system outflow, raising heart rate and peripheral vascular resistance (Landsberg, Journal of Hypertension, 2001).

• Second, insulin acts on the proximal renal tubule to enhance sodium-hydrogen exchanger activity, promoting sodium retention, volume expansion, and the pressure increase that follows (DeFronzo, Diabetologia, 1981).

• Third, insulin resistance effects in the vascular endothelium is not uniform: the PI3K-eNOS-nitric oxide vasodilatory pathway is selectively impaired while the MAPK-endothelin-1 vasoconstrictive pathway is preserved. The net result is a shift in vascular tone toward vascular constriction (Muniyappa and Sowers, Reviews in Endocrine and Metabolic Disorders, 2013).

• Fourth, visceral adipose tissue generates angiotensinogen locally, activating the renin-angiotensin-aldosterone system and adding a fourth independent pressure-elevating mechanism to the three already operating.

Conventional antihypertensive therapy mostly addresses the pressure reading. With the exception of ACEI/ARB class medications, most of these mechanisms are left unaddressed. If you have unexplained (often called essential) hypertension, ask your doctor for a lipid and pre-diabetes screening if you haven’t already. If visible obesity is already present despite normal laboratories, aggressive lifestyle modification needs to be an active part of your treatment.

An Unescapable Reality

The metabolic syndrome caused by a single underlying insult, insulin resistance, is one the most striking clinical manifestation illustrating the interconnected nature of the human body. We have come to think the human body as a collection of separate independent systems: nervous, cardiovascular, gastrointestinal, etc. We have treated diseases based on this foundation for years. The reality is that our body is a collection of tightly interconnected systems, a failure in one has measurable effects on every other.

Six organ systems remain: the heart, the kidneys, the liver, the airway during sleep, the brain, and the relationship between insulin resistance and malignant transformation.

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

Tags: insulin resistance, metabolic syndrome, type 2 diabetes, PCOS, hypertension, dyslipidemia, obesity, patient education